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“There can be no transforming of darkness into light and 
of apathy into movement without emotion.” 
 
Carl Gustav Jung 
(Swiss psychiatrist, psychologist and founder of the analytic psychology, 1875-1961) 
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1. Introduction 
 
Most people are familiar with motivation as an aspect of everyday behaviour. Just 
think about what drives you to learn? Why did you choose your career? Your 
partner? Where you would live? Simply put, motivation is WHAT drives you to 
behave in a certain way or to take a particular action. In modern psychology, the 
concept of motivation has largely been applied to study learning at school, 
performance at work, and competition in sport. In recent years, however, pioneers of 
neuropsychiatry have proposed to define a clinical syndrome of apathy characterized 
by a lack of motivation. Although disagreement regarding the concept and core 
features of apathy, most researchers agree that apathy is clearly distinct from 
depression and can be observed in healthy people as well as in several 
neurodegenerative disorders and in particular in Alzheimer’s disease (AD). The study 
of apathy is still in its infancy, but several validated apathy rating scales have made it 
possible to explore the universe of motivational deficits across diagnostic groups.  
 
In recent years, several studies of apathy in patients with Parkinson’s disease (PD) 
have shown that diminished motivation is a common but under-recognised 
behavioural disorder. However, further studies are needed to gain information about 
the frequency and clinical correlates of apathy from the time of diagnoses to more 
advancing stages of PD.  
 
The first part of this thesis gives a brief overview of PD and apathy in general. In the 
next section we review the current knowledge about apathy in PD. Finally, the main 
part of this thesis is devoted to our research which intends to describe apathy as a 
neuropsychiatric disorder in community-based patients with PD across different  
stages of disease. 
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2. Parkinson’s disease 
 
2.1 Historical background 
The English physician James Parkinson (1755-1824) was the first to publish an 
accurate description of the clinical syndrome that was later to bear his name. In his 
classical 1817 monograph entitled “An essay on the shaking palsy”, Parkinson 
described the clinical features of six subjects he had seen either as patients or 
observed on the streets close to his home in Hoxton Square, London.1 His treatise 
begins with a succinct summary of the distinctive features of the malady: 
 
“Involuntary tremulous motion, with lessened muscular power,  
in parts not in action and even when supported; with a propensity 
 to bend the trunk forwards and to pass from a walking to a running 
pace: the senses and intellects being uninjured.” 
 
Although the essence of his description of the disease was remarkably accurate, he 
did not identify abnormalities in muscle tone or cognition. However, Parkinson 
recognized several nonmotor features that occurred during the progression of the 
disorder, such as sleep disturbance, constipation, urinary incontinence, fatigue and 
delirium. More than half a century later, the French physician Jean-Martin Charcot 
(1825-1893) added muscular rigidity, micrographia, and sensory changes to the 
syndrome, and gave credit to Parkinson by referring to the disease as “maladie de 
Parkinson.” 
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A century passed after the original description by Parkinson before the Russian 
neuropathologist Constantin Tretiakoff (1892-1958) described degeneration of the 
substantia nigra associated with PD in his doctoral thesis of 1919.2 In 1957, Carlsson 
and colleagues discovered that the hypokinetic syndrome induced by the 
antipsychotic agent reserpine in experimental animals could be reversed by levodopa, 
a dopamine precursor that crosses the blood-brain-barrier.3 Soon thereafter the same 
group published a theory of dopamine as a neurotransmitter in the brain possibly 
involved in motor control.4 A few years later, Ehringer and Hornykiewicz 
demonstrated markedly decreased dopamine concentrations in the striatum of patients 
with PD,5 which led to the first trials of intravenous levodopa showing spectacular 
improvement of akinesia in patients with PD.6 In 1967, Cotzias and colleagues 
presented dramatic effects of large oral doses levodopa in PD patients7 and two years 
later levodopa was introduced as a clinically applicable therapy.8 
 
While the 1960s were the years of dopamine discovery and the 1970s the decade of 
efficient treatment of the disease by the introduction of dopamine replacement 
therapy, the 1980s witnessed motor complications due to chronic levodopa treatment. 
This led to the rebirth of surgical treatment in the 1990s by introduction of 
continuous deep brain stimulation (DBS) as a well-documented treatment for 
carefully selected patients with motor fluctuations and dyskinesias.9 In recent years, 
the identification of disease-related genes that cause hereditary forms of PD have led 
to novel insight into the pathogenesis of PD, that will hopefully offer novel 
therapeutic options.10 
 
2.2 Epidemiology 
PD is the second most common neurodegenerative disorder after Alzheimer’s 
disease, affecting approximately 0.3% of the entire population and 1-2% of those 
older than 60 years in industrialised countries.11 PD has been shown to be slightly 
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more predominant in males in some studies.11, 12 It is estimated that 5 million people 
worldwide have PD, with an average age at disease onset of approximately 60 
years.13 However, as much as 10% of people with the disease are younger than 45 
years of age.14 The prevalence rate of PD is affected by survival and study 
methodology (hospital-based surveys versus community-based studies). As a result of 
these methodological difficulties, crude prevalence rates in PD vary wildly between 
10 and 405 per 100,000 inhabitants.15 Most community-based prevalence studies 
across Europe, however, found crude prevalence rates between 100 and 200 per 
100,000 inhabitants.16 Incidence calculations are probably a better estimate of the 
frequency of the disease because they are not affected by mortality. Nevertheless, 
age-standardized annual incidence rates of PD in population-based studies in 
European countries and the USA range from 8 to 19 per 100,000 inhabitants,17 
probably due to differences in methods of ascertainment and case definition. Overall 
risk of PD increases with advancing age and both age-specific incidence and 
prevalence rise exponentially into the 70s and 80s but then decline in some studies,11 
probably due to poor case ascertainment and low numbers in these age groups. With 
the aging of the population, it is expected that the number of cases of PD will 
increase dramatically over the next decades.18 
 
2.3 Aetiology  
The cause of PD is still unknown, but current knowledge suggests that it is a 
progressive multisystem degenerative process with several potential causative 
factors.19 Several studies have shown a weak, but significant, increased risk of PD in 
people exposed to pesticides, rural living, farming, and well-water ingestion.20 In 
contrast, cigarette smoking and caffeine are associated with decreased risk of PD,21, 22 
and it has been suggested that a premorbid parkinsonian personality may account for 
this finding.23 Over the last 12 years, several genes causing monogenic parkinsonian 
syndromes have been discovered (Table 2.1). Genetic studies found mutations in 
autosomal dominant genes such as -synuclein (PARK1) and leucine-rich repeat 
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kinase 2 (LRRK2), as well as in autosomal recessive genes such as Parkin (PARK2), 
PINK1 (PARK6) and DJ-1 (PARK7). 
 
Table 2.1 Genetics of PD 
 
PINK = phosphatase and tensin homolog (PTEN)-induced putative kinase; LRRK = leucine-rich repeat kinase. 
From Gasser.24 
 
Although these genetic mutations are relatively rare (< 5% of patients) in sporadic 
cases of PD with no family history of the condition, they may elucidate possible 
pathogenetic pathways because of their suggested role in the ubiquitin-proteosome 
system, in oxidative stress response, and mitochondrial functions.10 The majority of 
PD cases are considered to be caused by the interaction of genetic and environmental 
factors, and susceptibility variants of genes involved in monogenic forms of PD have 
been identified in sporadic PD in several populations.25  
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2.4 Pathogenesis and pathophysiology 
2.4.1 Neuropathology 
The loss of dopaminergic, neuromelanin-containing neurons from the pars compacta 
of the substantia nigra is the pathological hallmark of PD. The resulting loss of 
neuromelanin from the substantia nigra leads to the depigmentation of this structure 
observed at post-mortem, but its role in the genesis of PD is unknown. It has been 
estimated that the clinical signs of PD do not develop until normal striatal dopamine 
levels are reduced by 80% and total cell loss in the substantia nigra reaches 50% 
(70% in the ventrolateral tier).26 This finding implies that the brain has excellent 
compensatory mechanisms, which consist of a presynaptic increase in the turnover of 
dopamine in surviving neurones and a postsynaptic increase in dopamine receptor 
sensitivity. Cell loss in PD is not confined solely to the substantia nigra but also 
affects the locus coeruleus, dorsal nuclei of the vagus, nucleus basalis of Meynert, 
raphe nuclei, sympathetic ganglia, hypothalamus and the ventral tegmental area.27  
 
The pathological determination of PD also includes the identification of Lewy 
bodies,28 which are eosinophilic hyaline inclusions present in the cytoplasm of some 
remaining neurons in the substantia nigra pars compacta. They can also be found in 
other catecholaminergic nuclei affected in PD, along with the cerebral cortex, 
thalamus, brainstem, intermediolateral column of the spinal cord, sympathetic 
ganglia, and myenteric plexus of the gastrointestinal tract. It was recently discovered 
that -synuclein is a major structural component of Lewy bodies.29 Although the 
presence of Lewy bodies is an essential feature of PD, it has also been described in 
other conditions such as multiple system atrophy (MSA), progressive supranuclear 
palsy (PSP), corticobasal degeneration (CBD), motor neuron disease, pantothenate 
kinase associated neurodegeneration (PKAN = Hallervorden-Spatz disease), AD, and 
Down’s syndrome.30 This probably implies that Lewy bodies are a common end-
product of neuronal degeneration. Lewy bodies have also been detected in the brains 
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of about 10% of clinically normal people over 60 years of age. This process is 
sometimes referred to as incidental Lewy body disease and might be a 
presymptomatic early phase of PD.31, 32 
 
In recent years, Braak and colleagues have used synuclein immunostaining 
techniques to document a new hypothesis on staging of the neuropathological process 
in PD (Figure 2.1).33, 34 Although their work supports the possibility of 
presymptomatic PD in patients with small numbers of Lewy bodies in the brainstem, 
it cannot explain the presentation of Lewy body dementia with cognitive dysfunction 
appearing before any motor features.35 
 
Figure 2.1 The neuropathological stages of sporadic PD 
 
PD presymptomatic and symptomatic phases. A The presymptomatic phase is marked by the appearance of 
Lewy neurites/bodies in the brains of asymptomatic persons. In the symptomatic phase, the individual 
neuropathological threshold is exceeded (black arrow). The increasing slope and intensity of the coloured areas 
below the diagonal indicate the growing severity of the pathology in vulnerable brain regions (right). The 
severity of the pathology is indicated by darker degrees of shading in the colored arrow left. B Diagram 
showing the ascending pathological process (white arrows). The shading intensity of the colored areas 
corresponds to that in A. From Braak et al.34 
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Based on recent findings that nerve cells implanted into the striatum of patients with 
PD develop PD pathology with loss of dopamine markers and classic Lewy bodies, it 
has been hypothesised that -synuclein acts like a prion and that PD may in fact be a 
prion disorder.36 
 
2.4.2 Neurochemistry 
In terms of neurochemical changes, the characteristic finding in PD is profound 
depletion of dopamine predominantly in the nigrostriatal system and to a lesser extent 
in the mesocortical and mesolimbic pathways.30 To date, a total of five subtypes of 
dopamine receptors have been cloned, which are grouped into D1-like (D1 and D5 
receptors) and D2-like (D2, D3, and D4 receptors) families.37 D1 and D2 receptors 
are mostly localized in the striatum and substantia nigra, D3 receptors are largely 
expressed in the ventral striatum and nucleus accumbens, D4 receptors are expressed 
in the frontal cortex, and D5 receptors are mostly localized in the mammilary and 
pretectal nuclei.38 In addition to impairment of the dopaminergic neurotransmission, 
loss of neurones from the locus coeruleus in the brainstem leads to cortical 
noradrenaline depletion, serotonin (5-hydroxytryptamine; 5-HT) is reduced in the 
striatum due to raphe nucleus involvement, and loss of cholinergic neurones from the 
nucleus basalis of Meynert leads to reduced cholinergic innervation of the neocortex 
and hippocampus.39 Reduction in the neuropeptides substance P, met-enkephalin, 
cholecystokinin and somatostatin in the basal ganglia in PD have also been 
demonstrated, but the functional impact of these changes are unclear.40 
 
2.4.3 Pathogenetic mechanisms 
Although the cause of neuronal degeneration in PD is unknown, several mechanisms 
have been proposed: 1) Abnormal protein processing due to dysfunction of the 
ubiquitin-proteasome system, 2) oxidative stress and free radicals, 3) mitochondrial 
 21
dysfunction, 4) apoptosis, 5) excitotoxicity, and 6) inflammation.41 These 
mechanisms are not mutually exclusive and may be intimately related, possibly 
triggered by genetic, environmental, or a complex gene-environmental interaction. 
 
2.4.4 Pathophysiology of basal ganglia 
Considerable effort has been made during the last two decades in understanding the 
functional anatomy of the basal ganglia. The classic model suggests a direct and 
indirect pathway connecting the striatum and the globus pallidus, with modulatory 
effects of the dopaminergic neurons on each of these systems (Figure 2.2).  
 
According to this model, the motor symptoms of PD are caused by nigrostriatal 
dopamine deficiency in the putamen, which results in increased activity in 
striatopallidal gabaminergic fibres (via enhanced activation by the indirect pathway 
and decreased inhibition by the direct pathway) and thereby inhibiting the lateral 
pallidal gabaminergic neurons to the subthalamic nucleus (STN). In this way the 
glutamatergic STN projection to the pallidum is stimulated, which increases the firing 
of medial pallidal gabaminergic neurons to the thalamus. This leads to increased 
inhibition of the thalamocortical pathway that suppresses movement. However, it is 
now appreciated that the basal ganglia are far more complex than previously 
understood and are comprised of a complex network of neurons with multiple 
feedback and feed forward loops rather than the linear pathways portrayed in the 
classic model.13 
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Figure 2.2 Schematic representation of the classic model of the basal 
ganglia  
 
 
Excitatory fibers are shown in white and inhibitory fibers in black. The model predicts that neuronal firing in 
the STN and GPi are increased in the parkinsonian state, leading to excessive inhibition of brainstem and 
thalamocortical neurons with the development of parkinsonian motor features. SNc = substantia nigra pars 
compacta; GPe = external globus pallidus; STN = subthalamic nucleus; VL = ventral lateral nucleus of the 
thalamus; Gpi = internal globus pallidus; SNr = substantia nigra pars reticularis; PPN = pedunculopontine 
nucleus; DA = dopamine. Adapted from Olanow et al.13 
 
2.5 Clinical features 
2.5.1 Cardinal motor signs 
Parkinsonism is a clinical syndrome defined by the presence of a combination of the 
cardinal motor signs of rest tremor, rigidity, bradykinesia, and postural 
abnormalities.42 
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Tremor 
A 4-6 Hz  rest tremor is the most common and easily recognised presenting feature of 
PD, affecting 60% to 70% of patients at motor onset.43-45 However, the percentage of 
patients with tremor at some point during the course of the disease is variable, 
ranging from 75% to 100%.44, 46, 47 The typical tremor of PD tends to start unilaterally 
in the hand, described as supination-pronation (“pill-rolling”) tremor, subsequently 
involving the ipsilateral leg or contralateral arm. Although the tremor on average 
spreads bilaterally six years after the onset of symptoms,48 the initially affected side 
continues to have more tremor than the contralateral side. Rest tremor in patients with 
PD can also involve the lips, chin and jaw, but head tremor in early disease is atypical 
and most likely caused by essential tremor or cervical dystonia.49 Many patients with 
PD also have tremor when the limb is placed in a position of postural maintance 
(postural “re-emergent” tremor), which is differentiated from essential tremor in that 
tremor is often delayed after the patients assumes an outstretched horizontal 
position.50 Rest tremor usually disappears at sleep, is reduced during action of the 
affected limb(s), and worsens by anxiety, emotional excitement and stressful 
situations. The response of tremor to drug treatment is highly variable.51 
 
Rigidity 
Rigidity is characterised by unvarying increased resistance throughout the range of 
passive movement of a limb (flexion, extension or rotation about a joint). The 
“cogwheel” phenomenon is a particular type of rigidity in some patients with PD, 
thought to be caused by tremor superimposed on increased tone.52 However, many 
will instead have “lead-pipe” rigidity, where the tonic resistance is smooth 
throughout the entire range of passive motion. The flexed posture resulting in flexed 
neck and trunk posture, as well as flexed elbows and knees, are often associated with 
rigidity, although generally occurs late in the disease.49 Patients may experience 
rigidity as stiffness associated with vague aching and discomfort of a limb, especially 
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in the shoulder where rigidity initially may be misdiagnosed as arthritis, bursitis or 
rotator cuff injury.53, 54 Rigidity often begins unilaterally, typically on the same side 
as the rest tremor if present, and eventually progresses to the contralateral side and 
remains asymmetric throughout the disease.48 The frequency of rigidity in patients 
with PD has only been reported in a few series, with values ranging from 89% to 
99%.55 
 
Bradykinesia 
Bradykinesia means slowness of movement and is one of the most disabling motor 
symptoms of PD. It is eventually seen in all patients and is considered a requirement 
for diagnosis of PD in many published diagnostic criteria. Patients with bradykinesia 
have difficulties with planning, initiating and maintaining movement in addition to 
performing sequential and simultaneous tasks.56 Patients often have a difficult time 
describing symptoms of bradykinesia, often using “weakness”, “incoordination”, and 
“tiredness” to describe their decreased ability to initiate voluntary movement. 
Bradykinesia may be clinically manifested as decreased eye blinking, micrographia, 
decreased finger dexterity, shuffling steps, difficulty arising from chair, and 
hypophonia, among others. Freezing (motor blocks) is a form of akinesia that is 
poorly understood and contributes to gait difficulty in PD. It usually does not occur 
until more advanced stages of PD and typically manifests as a sudden and transient 
(usually <10 seconds) inability to move, most commonly during walking.49  Like 
tremor and rigidity, bradykinesia often presents unilaterally, progresses slowly to the 
contralateral side of the body, and remains asymmetric throughout the disease.57 
 
Postural abnormalities 
Postural abnormalities in PD refer to changes in posture as well as gait problems with 
imbalance. The bent posture with flexion in the neck, trunk, and arms is probably due 
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to rigidity and muscle spasm. The typical parkinsonian gait is slow, small stepped, 
and shuffling. Postural imbalance is caused by impairment of centrally mediated 
postural reflexes, which are important to make rapid postural corrections. Falls are 
common in late PD and are a major cause of morbidity. They may be caused by either 
postural imbalance or a displaced centre of gravity due to flexed posture. 
 
2.5.2 Other motor abnormalities 
PD patients may also exhibit a number of secondary motor symptoms, which are 
mostly variants of one or more of the cardinal signs. Hypomimi, or loss of facial 
expression, is most likely caused by a combination of both bradykinesia and rigidity. 
Bulbar dysfunction manifested by dysartri, hypophonia, dysphagia and sialorrhoea 
are frequently observed in patients with PD and are thought to be related to orofacial-
laryngeal bradykineasia and rigidity.58 Some PD patients develop restrictive or 
obstructive respiratory disturbances due to rigidity in the neck and chest wall.59 
Respiration may also be compromised by levodopa related respiratory dyskinesia.60 
Respiratory problems in patients with PD are associated with substantial morbidity 
and mortality.49 A number of oculomotor abnormalities have been described in PD 
patients, such as decreased blink rate, positive glabellar reflex, and upgaze limitation, 
among others.61 
 
2.5.3 Nonmotor features 
While PD has traditionally been considered a motor system disorder, it is now widely 
recognized that nonmotor symptoms of PD are common, occur across all stages of 
PD, are underreported, and are a key determinant of reduced functioning and quality 
of life.62 In a hospital-based cross-sectional study of 99 nondemented patients with 
PD, only 12% of the sample had no anxiety, depression, fatigue, sleep disturbance, or 
sensory symptoms after seven years of disease duration.63 Nonmotor symptoms of PD 
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occur both in early and advanced stages, and some symptoms such as olfactory 
deficit, constipation, rapid-eye movement (REM) sleep behaviour disorder (RBD), 
and depression might even precede the onset of motor symptoms by several years.64 
A recent hospital-based study of 101 PD patients demonstrated that during routine 
office visits, neurologists failed to identify the presence of anxiety, depression and 
fatigue in over 50% of cases, and sleep disturbance in over 40% of patients.65 
Numerous studies have shown that nonmotor symptoms significantly impair quality 
of life and may precipitate hospitalisation in patients with PD.66 The spectrum of 
nonmotor manifestations of PD is broad, as shown in Table 2.2. This section will 
focus on cognitive deficits and depressive disorders, whereas apathy in PD will be 
discussed in detail in chapter 4. 
 
Table 2.2 Nonmotor features of Parkinson’s disease 
 
From Poewe.67 
 
 
 
 27
Cognitive impairment and dementia 
Cognitive impairment is commonly associated with PD. The frequency of cognitive 
dysfunction in patients with PD without clinical evidence of dementia was reported to 
be 36% at the time of PD diagnosis.68 At a mean of 3.5 years follow-up, 10% of the 
incident PD cohort had developed dementia and further 57% showed evidence of 
cognitive impairment.69 A recent study has demonstrated a twofold increase in the 
proportion with cognitive impairment in patients with early untreated PD compared 
to matched controls.70 Executive functions, memory, visuospatial skills, attention, and 
mental processing speed are the most frequently encountered domains of cognitive 
dysfunction in non-demented patients with PD.71-73 With increasing disease duration 
of PD, the severity and range of cognitive deficits typically increase. However, core 
language functions are likely to remain intact for the most part of the disease 
process.74 Prevalence studies of dementia in PD vary depending on the age, disease 
duration, and population surveyed.75 The point prevalence of PD dementia (PDD) has 
been estimated to approximately 30%, which accounts for 3-4% of dementia in the 
general population.75 However, it is likely that this is an underestimate of the true 
frequency, as highlighted by two recent longitudinal studies with 12 and 20 years of 
duration76, 77 reporting over 80% of PD patients with dementia. A six-fold increased 
risk of developing dementia in PD compared to non-PD subjects has been 
demonstrated.78 Risk factors for PDD include advanced age,79 mild cognitive 
impairment69 and severity of parkinsonism, particularly axial symptoms like postural 
instability and speech problems.80, 81 New consensus criteria for a clinical diagnosis 
of PDD have recently been proposed.74  
 
Depressive disorders 
Depression is one of the most common neuropsychiatric disorders in PD patients with 
significantly higher prevalence rates than in age-matched controls and patients with 
other chronic diseases.82, 83 About 20% of patients report depressive symptoms 
 28 
preceding the motor onset of PD, and depressed patients have a two-three fold 
increased risk of developing PD compared to non-depressed control subjects.83, 84 The 
prevalence of depression has varied widely between different studies depending on 
the definitions, assessment instruments, and the population studied.85 In a recent 
systematic review of prevalence studies in PD, the weighted prevalence of major 
depression, minor depression and dysthymia was 17%, 22% and 13%, respectively.86 
In the general population these numbers were lower, whereas higher prevalence rates 
were found in hospital outpatient and inpatient settings. For example, Tandberg and 
colleagues reported that 7.7% of patients with PD in the community met the criteria 
for major depressive disorder82 according to criteria of the Diagnostic and Statistical 
Manual of Mental Disorders, 3rd Edition, Revised (DSM-III-R).87 Despite their high 
prevalence, depressive disorders are frequently undiagnosed in PD.65 One important 
reason is the potential overlap between some core features of depression with motor 
symptoms of PD. For example, bradykinesia and facial masking resemble the 
psychomotor slowing, decreased initiative, and restricted affect seen in major 
depression or apathy.88 In addition, several cognitive, vegetative, and somatic 
symptoms of major depression are commonly seen in patients with PD who do not 
have depression.89 Based on these challenging aspects of recognition of depressive 
symptoms in PD, provisional diagnostic criteria for depression in PD have recently 
been recommended.90 The clinical profile of depressive disorders associated with PD 
generally resemble those of non-PD major depression, although anxiety, dysphoria, 
and irritability may be more prominently present in patients with PD, whereas self-
blame tendencies, feelings of guilt, and suicidality are less prevalent.91 Major 
depression, in contrast to minor (dysthymic) depression, has been significantly 
related to deficits in executive functions and the akinetic-rigid variant of PD, and 
predicts a faster cognitive and physical decline.92 To date, right-sided onset of motor 
symptoms is the only disease-specific marker of depression found in PD.93  
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2.6 Diagnosis and differential diagnosis 
Although PD is the major cause of parkinsonism, the earliest symptoms are often 
subtle and this can lead to misdiagnosis.94 Strict diagnostic criteria have been shown 
to increase the accuracy of a pathology diagnosis of PD.95Associated features such as 
asymmetry of motor onset, presence of resting tremor, and good response to 
dopamine medication therapy may help to distinguish PD from other parkinsonian 
disorders (Table 2.3).  
 
Table 2.3 Differential diagnosis in parkinsonian disorders 
 
From Alves et al.96 
 
Early occurrence of gait dysfunction, severe dysautonomia, hallucinations, dementia, 
or supranuclear gaze palsy are uncommon and suggestive of parkinsonism due to 
other neurodegenerative disorders. Structural brain imaging, using computed 
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tomography (CT) and magnetic resonance imaging (MRI), is mainly used to exclude 
secondary causes of parkinsonism, but may also be helpful in distinguishing between 
PD and atypical parkinsonian syndromes like MSA and PSP. Functional brain 
imaging, using dopamine-ligands in single-photon emission computed tomography 
(SPECT) and positron emission tomography (PET), can be helpful to establish the 
clinical diagnosis of PD in uncertain cases but is not reliable when distinguishing PD 
from atypical forms of parkinsonism.   
 
2.7 Treatment 
At present, no preventive or curative treatment for PD is available, and thus 
pharmacotherapy may only provide symptomatic effects on motor and, to a less 
extent, nonmotor symptoms in PD. Although most treatment strategies focus on 
pharmacologic agents, exercise and lifestyle changes, as well as speech therapy may 
be helpful in some patients. Guidelines for the management of PD are produced on a 
regular basis.97-99 In the following the major pharmacologic and surgical treatment 
modalities for PD will be addressed. 
 
MAO-B inhibitors 
Selegiline is an irreversible inhibitor of monoamine oxidase type B (MAO-B), which 
reduces the breakdown of dopamine in the striatum. Although selegiline has been 
shown to delay disease progression in PD,100, 101 which may indicate neuroprotective 
properties, the results are not yet conclusive.102 Selegiline can be used as initial 
monotherapy in PD or as adjuvant therapy once motor complications have developed 
on levodopa. Of notice, because selegiline is metabolised to amphetamine derivates, 
it may cause insomnia, nightmares and hallucinations. Recently, a new second 
generation irreversible MAO-B inhibitor, rasagiline, has been suggested to induce 
neuroprotective effects similar to those of selegiline.103 Rasagiline does not 
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metabolise to amphetamine derivates, reducing the side-effects experienced with 
selegiline. Indication for treatment with rasagiline in PD is the same as for selegiline. 
There are currently no comparative studies of rasagiline and selegiline.. 
 
Levodopa 
Forty years after its introduction, levodopa remains the most efficacious drug for 
symptomatic treatment of PD.104 Levodopa is a precursor of dopamine that crosses 
the blood-brain barrier and is decarboxylated to dopamine in the presynaptic terminal 
by dopaminergic neurons. To reduce the peripheral metabolism of levodopa, which 
causes nausea, and increase the availability of levodopa in the brain, it is usually 
administered with a peripheral dopa decarboxylase inhibitor such as carbidopa or 
benserazide. Levodopa provides rapid and effective relief of bradykinesia and rigidity 
with associated pain, and improves tremor in many patients. However, long-term 
levodopa therapy is associated with more frequent development of motor fluctuations 
and dyskinesias compared to other dopaminergic drugs. In addition, symptoms such 
as postural instability, speech disturbance and sialorrhea may not be improved due to 
non-dopaminergic mechanisms of PD. Levodopa is usually the preferred treatment of 
early PD with onset over age 70 years, as these patients are less prone to develop 
serious long-term motor complications due to a rather short life-expectancy. 
 
Dopamine agonists 
Dopamine agonists act directly on postsynaptic dopamine receptors without the need 
for oxidative metabolism.105 Furthermore, most dopamine agonists have significantly 
longer half-lives than levodopa and thus provide more continuous dopaminergic 
receptor stimulation. The pulsatile dopamine receptor stimulation caused by non-
continuous delivery of levodopa has been hypothesized as a critical factor for the 
development of dyskinesis.106 Indeed, several controlled trials have shown that initial 
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therapy with dopamine agonists is associated with less rapid development of motor 
fluctuations and dyskinesias compared to initial treatment with levodopa.107 
Dopamine agonists are broadly divided into ergot and non-ergot agonists, which all 
act on D2-like dopamine receptors. However, different dopamine agonists have 
selective subspecificities within the D2-family (D2, D3, and D4 receptors) and this 
may offer the potential of specific clinical profiles and different adverse reactions 
accociated with specific types of receptor stimulation. It is now current practice to 
initiate non-ergot dopamine agonists (pramipexole, ropinorole, and rotigotine) instead 
of ergot-derived agonists to avoid serosal reactons and cardic valvulopathy (pergolide 
and carbegoline). To avoid common side-effects such as nausea, vomiting, ortostatic 
hypotension, and daytime sleepiness, doses are generally increased very slowly. 
Dopamine agonists are usually preferred as initial monotherapy in patients with 
younger age,108 but may also be given as adjuncts to levodopa in later disease. 
 
COMT inhibitors 
Catechol-O-methyltransferase (COMT) is the main enzyme responsible for the 
metabolism of levodopa after dopa decarboxylase inhibition. Entacapone is a 
reversible peripheral COMT inhibitor that increases serum half-life of levodopa by 
inhibiting its conversion into 3-O-methyldopa, thereby prolonging its duration of 
action. When administered in combination with levodopa, entacapone reduces off-
time and increases on-time which allows a reduction in levodopa dose.109 Entacapone 
is approved for adjunctive therapy in patients with motor fluctuations. A triple 
combination tablet containing entacapone/levodopa/carbidopa is currently available 
and may improve compliance which is known to be a problem in PD. COMT 
inhibitors cause dopaminergic side-effects (nausea, vomiting, and dyskinesias) along 
with diarrhoea and yellow discolouration of urine.  
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Other medical management and responses 
Amantidine and anticholinergic drugs have limited symptomatic effect and may cause 
significant adverse effects such as confusion and hallucinations, especially in older 
patients and those with dementia. These drugs are no longer recommended for routine 
use in PD in Norway. Of notice, placebo-associated responses could lead to an initial 
20% improvement in motor scores.14 This improvement is hypothesized to be 
mediated through mesolimbic dopaminergic pathways.110, 111 
 
Surgical treatment 
Functional neurosurgery may be appropriate for a small number of PD patients with 
severe motor complications (motor fluctuations and/or dyskinesias) or disabling 
tremor that cannot be managed by medical therapy. DBS has now largely replaced 
lesional therapy because the effect of electrical stimulation is adjustable and 
reversible. During the last decade, DBS of the STN has become the gold standard 
neurosurgical treatment for motor complications in PD. Younger age, shorter disease 
duration, and a positive response to levodopa (levodopa challenge response) predict a 
favourable outcome.112 Patients should not have severe cognitive, behavioural, or 
psychiatric problems such as depression, or other medical conditions that would 
increase the risk of surgery. Multiple studies have reported substantial long-term 
benefits of DBS STN regarding motor function and motor complications.113, 114 
However, progression of PD and worsening of axial symptoms as well as 
development of dementia did occur.113 Recent reports suggest that DBS of the 
pedunculopontine nucleus (PPN) could improve drug-resistant gait freezing and 
postural instability in advanced PD, especially when combined with DBS of the 
STN.115 However, further studies in more patients are needed to fully explore the 
benefit of PPN as a new target for STN. 
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2.8 Prognosis and complications 
Although PD is still an incurable chronic progressive disease, quality of life and 
functional capacity is usually substantially improved in the first period after 
symptomatic therapy is introduced. Some studies in early PD suggest that on average 
five years after initiation of drug therapy, severity of motor impairment and disability 
return to pre-treatment levels.116, 117 With the progression of the disease higher doses 
of dopaminergic treatment are necessary to maintain motor function. Eventually, 
many patients develop long-term motor and psychiatric side-effects. The Sydney 
Multicentre Study of PD118 recently found no differences in the Hoehn and Yahr 
staging in their patients after 15 years of treatment when compared to data from the 
classic pre-levodopa study by Hoehn and Yahr.119 The authors concluded that modern 
treatment does not lead to significant long-term benefit in patients with PD. 
Noteworthy, there is remarkable interindividual variation in the progression of PD. 
Prospective longitudinal studies suggest that especially higher age at motor onset,120, 
121 and to a lesser degree a postural instability and gait disorder (PIGD) motor 
subtype, lack of rest tremor, more severe functional impairment, and cognitive 
dysfunction 122-124 are risk factors for more severe functional decline in PD. In 
contrast, cigarette smoking, coffe and tea consumption, and pesticide exposure appear 
not to impact the rate of motor progression in patients with PD.125-127 
 
Progressive disease, postural instability, and freezing are common risk factors for 
falls and hip fractures in patients with PD.128, 129 Prominent hallucinations seems 
largely responsible for nursing home placement, 130, 131 and the risk for dementia is up 
to 6 times higher in patients with PD than in healthy people.78 Despite modern 
treatment, life expectancy is still decreased in PD relative to control subjects. In a 
recent comprehensive review, mortality hazard ratios ranged between 1.5 and 2.7 in 
several European countries, Australia and the USA.11 Dementia seems to be the 
highest risk factor for shortened life.132 The cause of death in patients with PD are 
often related to immobility and fatal infections.133 
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3. Apathy 
 
3.1 Historical perspective 
The word apathy stems from the Greek apatheia derived from apathes,  “a” (without) 
+ “pathos” (passion), and was originally coined by the Greek Stoic philosophers 
more than 2000 years ago to refer to the condition of being free from emotions and 
passions. The Stoics considered apatheia the only human lifestyle leading to a 
virtuous and happy life, whereas states of extreme emotions - such as fear, pain, 
desire and pleasure - would incline humans towards irrational behaviours.134 The 
great humanists of the Renaissance used the term apathy in its ancient meaning, but 
by the early 19th century the term apathy was used to describe loss of normal 
psychological function, for example “apathie affective” and “apathie 
intellectuelle.”134 During the last 20 years, the work of Robert Marin has served as a 
major stimulus to research interest in apathy. Marin proposed a specific set of 
diagnostic criteria and validated ad hoc scales,135, 136 which are still by many 
considered gold standard. 
 
3.2 Challenges in defining and assessing apathy 
3.2.1 Different concepts of apathy 
In the early 1990s, Marin proposed to define apathy as a primary lack of motivation 
that manifests itself as reduced goal-directed behaviour (e.g. lack of initiative, 
productivity and effort), reduced goal-directed cognition (e.g. lack of intellectual 
interest and curiosity), and reduced emotional concomitants of goal-directed 
behaviour (e.g. flattened affect and lack of emotional response to positive or negative 
events).135 He defined motivation as the direction, intensity and persistence of goal-
directed activity. Marin also considered apathy to be a distinct neuropsychiatric 
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syndrome if the primary lack of motivation was not attributable to diminished level of 
consciousness, cognitive impairment or emotional distress.  
 
Because apathy frequently occurs in patients with dementia or depression, Sergio 
Starkstein proposed to broaden Marin’s criteria to include patients with apathy in the 
context of depression, dementia, or other neurodegenerative diseases.137 Recently, 
Starkstein and Leentjens proposed to include a time criterion to ascertain the 
persisting nature of apathy, i.e. the symptoms had to be present for at least 4 weeks 
during most of the day.134 
 
Donald Stuss and colleagues argued that the definition and assessment of motivation 
is problematic, and suggested to define apathy as an absence of responsiveness to 
stimuli as demonstrated by a lack of self-initiated action. They considered employing 
syndromal criteria for apathy to be potentially limiting, and suggested instead to 
divide apathy into separable types or states that differ in both functional disturbances 
underlying the clinical presentation and neural substrates of involvement.138 
 
Recently, Levy and Dubois criticized lack of motivation to be an obscure 
psychological concept, and suggested to define apathy as an observable behavioural 
syndrome consisting of a quantitative reduction of voluntary (or goal-directed) 
behaviours. They considered apathy to be related to disruption of emotional-affective, 
cognitive, and auto-activation processes in the prefrontal cortex-basal ganglia 
circuits.139  
 
Modern conceptualizations of apathy include various dimensions of apathy (Table 
3.1). Although disagreements as to whether disorders of motivation135 or of initiative 
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and self-generated voluntary and purposeful behaviour 138, 139 are core features, most 
conceptualizations consider apathy a neuropsychiatric syndrome which includes most 
of these dimensions. 
 
Table 3.1 Concepts of apathy 
Author Concept 
Marin et al.136  Disorder of motivation with cognitive, sensory, motor 
and affective subtypes 
Cummings et al.140 Disorder of interest or motivation; including lack of 
emotion, lack of initiation, lack of enthusiasm 
Stuss et al.138 Disorder of initiative, manifesting lack of self-initiated 
action, which may be affective, behavioural or 
cognitive and includes ‘‘social apathy’’ – a disorder of 
sense of self and of social awareness  
Robert et al.141  Disorder of motivation with emotional blunting, lack 
of initiative, lack of interest 
Sockeel et al.142 Disorder of intellectual curiosity, action initiation, 
emotion and self-awareness 
Levy and Dubois139 Disorder of voluntary and goal-directed behaviours; 
with three subtypes of disrupted ‘‘signal’’ processing: 
– emotional-affective, cognitive and auto-activation 
Starkstein and Leentjens134 Disorder of motivation with diminished goal-directed 
behaviour and cognition 
From Robert et al.143 
 
3.2.2 Apathy is not depression 
Apathy has traditionally been viewed as a feature of depression due to overlapping 
symptoms such as diminished interest, psychomotor retardation and concentration 
difficulties. In fact, the Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition (DSM-IV)144 allows the diagnosis of primary major depression in the absence 
of depressed mood provided that markedly diminished interest or pleasure is 
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accompanied by four other common symptoms. The category of minor depression 
has recently been shown to include a relatively large proportion of individuals with 
apathy rather than a “true” affective disorder in PD patients, indicating that minor 
depression should be diagnosed using the DSM-IV criteria only when sad mood is 
present.145 While apathetic patients are emotionally indifferent, dysphoric feelings 
(sadness, guilt, and pessimistic thoughts) are typical for depression. Thus, depressed 
mood is a key distinguishing feature between apathy and depression. Despite the 
overlapping phenomenology between these two syndromes, several studies have 
shown that apathy in various diagnostic groups can be distinguished from depression 
in the sense that some patients have apathy but not depression, and vice versa.146 The 
potential neuroanatomical differences underlying these two distinct syndromes have 
yet to be determined. Interestingly, in a volumetric MRI-based study of the prefrontal 
cortex in 84 elderly subjects with or without major depression, the depressed group 
had smaller orbitofrontal gray matter volumes compared to the age-matched normal 
comparison group, whereas apathy was associated with decreased gray matter volume 
in the right anterior cingulate gyrus.147 
 
3.2.3 Relation to cognitive decline and dementia 
Mental slowing and poor concentration may be part of both apathy and cognitive 
decline or dementia. In fact, several studies have shown that apathy is associated with 
executive dysfunction and dementia in various diagnostic groups.146 However, 
whether cognitive deficits are necessary to produce apathy, or if apathy causes 
cognitive impairment, has not been specifically examined. As is the case with 
depression,148 some would argue that apathy should be included as part of a 
dysexecutive syndrome.149   
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3.3 Diagnostic criteria  
Recently, a task force including members of the Association Française de Psychiatrie 
Biologique, the European Psychiatric Association (EPA), the European Alzheimer’s 
Disease Consortium and experts from Europe, Australia and North America has 
formulated new criteria regarding apathy in dementia and neuropsychiatry (Table 
3.2).  
 
Table 3.2  Apathy proposed criteria 
 
From Robert et al.143 
 
The task force chaired by Philippe Robert discussed an advanced draft at a consensus 
meeting held during the EPA conference in April 7th 2008, and a final agreement 
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concerning operational definitions and hierarchy of the criteria was reached.143 This is 
the first formal consensus on diagnostic criteria for apathy in neuropsychiatric 
disorders. According to this consensus report, apathy is defined as a disorder of 
motivation that persists over time with the following requirements: 1)The core feature 
of apathy, diminished motivation, must be present for at least four weeks; 2) two of 
the three dimensions of apathy (reduced goal-directed behaviour, cognitive activity, 
and emotions) must be present; 3) functional impairment attributable to apathy should 
be identifiable; and 4) exclusion criteria regarding symptoms and states that mimic 
apathy are specified. Importantly, the task force has attempted to formulate the 
criteria in such a way that they may be applied to disorders beyond dementia and 
neuropsychiatric disorders. 
 
3.4 Differential diagnosis 
In clinical practice and research, several neuropsychiatric syndrome definitions that 
share one or more symptoms with the apathy syndrome, are still regularly used. The 
nosological position of these syndromes in relation to the concept of apathy, 
however, still remains uncertain.134 In addition to depression and dementia, as 
previously mentioned, these syndromes include abulia, akinetic syndromes, despair 
and demoralisation. 
 
Abulia 
The term abulia, stemming from the Greek “a” (without) + “boule” (will), has been 
defined as a lack of will or motivation or an inability to decide.150 Marin reserved this 
diagnosis for “patients who are awake but otherwise severely impaired in their ability 
to communicate and to initiate and self-regulate purposeful behavior”, and considered 
abulia to be a more severe form of apathy.150 Bhatia and Marsden defined abulia as 
“apathy with loss of initiative and of spontaneous thought and emotional responses”, 
 41
and described this syndrome in relation to basal ganglia lesions.151 More recently, a 
consensus report by British neurologists and psychiatrists included eight typical 
features of abulia,152 and acknowledged that in clinical practice the terms apathy and 
abulia were often used interchangeably. 
 
Akinetic syndromes 
Several akinetic syndromes have been described.134 Starkstein reported a severe loss 
of drive and motivation, known as psychic akinesia, in patients with bilateral 
ischaemic lesions to the globus pallidus.153 These patients display no goal-directed 
activity, but may perform most of their daily activity if they are strongly stimulated. 
Laplane and Dubois described a similar basal ganglia related syndrome labelled auto-
activation deficit,154 and defined this condition as “a deficit in spontaneous activation 
of mental processing, observed in behavioural, cognitve, or affective domains, which 
can be totally reversed by external stimulation that activates normal patterns of 
response”. Starkstein argued that it is almost impossible to separate abulia from the 
auto-activation deficit because the concept of these two syndromes are poorly 
defined.134 Habib used the term athymhormia, from the Greek “a” (without) + 
“thumos” (mood) + “horme” (impulse), to define a syndrome characterized by “a 
striking reduction in spontaneous motion and speech, with subadjacent mental 
emptiness and, maybe the crucial point, an apperent flatness or at least poor 
expressiveness of affect.”155 He further stressed that patients with athymhormia are 
not depressed, and suggested that this syndrome was caused by disruption at the 
emotional-limbic level. Cummings have described patients with akinetic mutism as 
profoundly apathetic: they typically have their eyes open, do not speak 
spontaneously, answer questions in monosyllables if at all, move little, are 
incontinent, eat and drink only if fed, display no emotion even when experiencing 
pain and are indifferent to their dire circumstances.156 Recently, Marin and Wilkoscz 
defined akinetic mutism as total absence of spontaneous behaviour and speech 
occurring in the presence of preserved visual tracking.157 They also considered 
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apathy, abulia and akinetic mutism as disorders of motivation that lie one a 
continuum, with apathy the least severe and akinetic mutism the most severe 
manifestation of diminished motivation. 
 
Despair and demoralisation 
These psychological states occur primarily in normal individuals in response to the 
experience of overwhelming stress or severe changes in their social environment.150, 
158 Although despair and demoralisation share with apathy the symptom of loss of 
motivation, apathy denotes a lack of concern or emotional distress, whereas despair 
and demoralisation are considered dysphoric, unpleasant states characterized by 
pessimistic or hopeless orientation toward the future.150, 158  
 
3.5 Common conditions associated with apathy 
Based on clinical experience and scientific research, apathy and more severe 
disorders of diminished motivation have been reported in numerous medical, 
neurological and psychiatric disorders, as well as secondary to drug abuse and 
institutionalization (Table 3.3). There is no evidence that damage to any one 
structure, neural pathway or region of the brain is uniquely responsible for producing 
apathy.159 Nevertheless, damage or dysfunction or abnormal connectivity within 
specific frontal-subcortical circuits leads to an increased probability of the occurrence 
of apathy,159, 160 see next section. 
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Table 3.3 Conditions associated with apathy, abulia, and akinetic 
mutism 
 
From Marin et al.157 
 
3.6 Neurobiology of apathy 
Present knowledge about the neurobiology of apathy derives from an understanding 
of the neural basis of motivation.161 Some of this research has been carried out in 
humans, but the majority of knowledge about the connectivity, neurochemistry, and 
physiology of the neural systems involved in motivated behaviour is derived from 
experimental studies in animals.160-162  
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3.6.1 Neurocircuitry 
Kalivas and colleagues have presented an elegant model describing four distinct 
neural subcircuits that are believed to provide the neural basis of motivation.160, 162, 163 
 
Subcircuit number 1 
Components: the ventral tegmental area (VTA), nucleus accumbens (NA), and the 
ventral pallidum (VP). Function: provides a “motivational working memory” that 
allows the prioritization of motivational valencies across the temporal domain.  
 
Subcircuit number 2 
Components: the VP, medial dorsal nucleus of the thalamus (MD), prefrontal cortex 
(PFC), NA, and the VTA. Function: provides the cognitive colouring of motivation. 
 
Subcircuit number 3 
Components: the VP, PPN, and the VTA. Function: integration of arousal into 
motivation. 
 
Subcicuit number 4 
Components: the VTA, amygdala, and the NA. Function: integration of “reward 
memory” (ie, incentive value) into motivational response. 
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These four subcircuits constitute the motivational circuitry (Figure 3.1) responsible 
for “translating motivation into action, receiving and integrating information about 
the organism’s past and present, and transforming it to cognitive, autonomic, and 
motor outcomes that hopefully will lead to goal attainment.”160  
 
Figure 3.1 The motivational circuitry 
 
The motivational circuitry responsible for translating motivationally relevant environmental stimuli into 
adaptive responses. The circuit lies partly in classic limbic structures, such as the amygdala and hippocampus, 
and transmits to classic motor output systems, such as the motor cortex, basal ganglia, and the reticulospinal 
tract. PFC = prefrontal cortex. MD = mediodorsal thalamus. VTA = ventral tegmental area. NA = nucleus 
accumbens. VP = ventral pallidum. PPN = pedunculopontine motor region. Adapted from Kalivas et al.162 
 
Limbic input from amygdala and hippocampus modifies information in the 
motivational circuitry on the basis of the current environment.157 Experimental 
studies have also shown that the anterior cingulate (AC) plays an essential role in 
motivational aspects of decision making.157 The AC, NA, VP, and MD comprise an 
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“affective” striato-thalamo-cortical circuit (Figure 3.2) thought to mediate 
motivation.161, 162  
 
Figure 3.2  Striato-thalamo-cortical circuits and their interactions with 
limbic structures 
 
The amygdala and other limbic structures involved with motivational and emotional processes, provide input 
via the ventral striatum, thalamus and cortex. These offer many direct and indirect opportunities for the 
emotional and motivational processses to influence the activity of other circuits including those concerned with 
cognition and motor function. Abbreviations: ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal 
cortex; Pe, globus pallidus external section; GPi, globus pallidus internal segment; MD, mediodorsal; MOFC, 
medial orbitofrontal cortex; PMC, premotor cortex; SMA, supplementary motor area; SNpc, substantia nigra 
pars compacta; SNr, substantia nigra pars reticulata; STN, subthalamic nucleus; VA, ventroanterior; VL, 
ventrolateral; VM, ventromedial; VTA, ventral tegmental area. From Pluck and Brown.159 
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Disruption of this circuit - also known as the anterior cingulate circuit - produces 
akinetic mutism, abulia, or apathy depending on the structure damaged and the 
severity of the dysfunction.164 Cummings has described an anterior cingulate 
syndrome 156 where patients are profoundly apathetic, i.e. present with symptoms of 
akinetic mutism caused by bilateral anterior cingulate injury. In contrast, unilateral 
lesions produce transient akinetic mutism. 
 
The dorsolateral prefrontal circuit, which is part of the nonmotor frontal-subcortical 
circuitry (Figure 3.3), subserves executive function and is responsible for integrating 
motivationally relevant information into cognitive and behavioural responses.165 A 
strong correlation between apathy and executive dysfunction has been reported across 
various diagnostic groups.146, 166 Finally, apathy may present as an accompanying 
symptom associated with personality changes caused by lesions of the lateral 
orbitofrontal circuit.156 
 
The current state of the motivational circuitry determines the behavioural response 
via projections to motor cortex, basal ganglia, and brain stem (Figure 3.1). 
Traditionally, motor output systems operate via motor cortex and basal ganglia. 
However, recent research has suggested that motivational output has access to 
autonomic and locomotor centers of the brain stem via the PPN,167 which in turn 
sends projections to the reticulospinal tract. Stimuation of the PPN results in 
autonomic behaviours such as fight or flight and stereotypic rhythmic displays.160 
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Figure 3.3 The nonmotor frontal-subcortical circuitry 
 
Organization of the three frontal-subcortical circuits in which lesions produce alterations of cognition and 
emotion. VA indicates ventral anterior; MD, medial dorsal. The indirect circuits and connections of the 
substantia nigra and the subthalamic nucleus are not shown. From Cummings.156 
 
3.6.2 Neurochemistry 
The chemical coding within the motivational circuitry is complex and not fully 
established. However, knowledge of the major elements is helpful to an 
understanding of clinical disorders of motivation. 
 
The substantia nigra is the principal source of striatal dopamine and the VTA is the 
major source of dopamine within the mesocortical and mesolimbic systems.168, 169 
Modulation of dopamine activity regulates changes in arousal, motivation, 
sensorimotor integration, and locomotor response.160 The dorsal striatum (putamen 
and caudate nucleus) is less sensitive to dopamine than the ventral striatum (primarily 
nucleus accumbens) and is involved in sensorimotor integration and the generation of 
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stereotypic behaviours.160 The ventral striatum, however, is essential in mediating the 
communication between neural systems involved in motivation, emotion, and 
locomotor response that is necessary for generation of complex flexible 
behaviours.160 Subcortical dopamine activity in the NA and VTA is partly regulated 
via excitatory amino acids from the medial PFC, amygdala and hippocampus (Figure 
3.4).160, 170 Dysfunction within these structures appears to decrease the threshold 
necessary for dopamine activation under stressful conditions, leading to excessive 
arousal and increased spontaneous motor behaviour.160 
 
Figure 3.4 Neural circuitry mediating the activiation of  
goal-directed behaviour 
 
  From Kalivas and Volkow.170 
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The mesencephalic locomotor region (primarily the nucleus basalis of Meynert and 
the PPN) appears to modulate the motivational circuitry via cholinergic projections to 
the limbic system, extrapyramidal system, thalamus, tectum (dorsal portion of the 
midbrain composed of the paired superior and inferior colliculi), and cortical 
regions.171 These ascending projections regulate dopamine efflux from the 
nigrostriatal neurons, and thereby influence motor behaviour.171 Therapeutic benefit 
of cholinesterase inhibitors for treating apathy in demented patients supports the 
modulatory effect of cholinergic systems on motivated behaviour.163 
 
The modulatory role of serotonin (5-HT) on motivation is extremely complex 
because receptor subclasses vary significantly with respect to their effect on 
cholinergic and dopamine activity.172 Serotoninergic fibers originating in the raphe 
nuclei of the midbrain project to almost all brain areas, including mesolimbic 
structures and cortex.173 It has been suggested that serotonin may increase motivation 
via 5-HT3 receptors that enhance mesolimbic dopamine activity in the VTA and 
NA.163 In contrast, selective serotonin reuptake inhibitors (SSRIs) have been reported 
to induce apathy in different patient groups.174, 175 Long-term SSRI therapy causes 
prolonged and excessive serotonin in the synapse and is proposed to decrease 
dopamine transmission in the frontal lobe,176 which may eventually lead to 
diminished motivation and apathy.175 
 
3.7 Evaluation and treatment of apathy 
Evaluation 
During routine office visits, primary care physicians and neurologists are less likely 
to recognize apathy than depression or cognitive impairment. There are several 
possible explanations for this.177 First, apathetic patients may be unaware of their own 
behavioural changes, i.e. lack insight, and are therefore unlikely to be motivated to 
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report this problem to the physician. Second, disorders of emotion (positive 
symptoms) are generally more emphasized by physicians than disorders of 
motivation (negative symptoms). Finally, recognition of behavioural symptoms is 
affected by the time constraint of the medical office visit and the fact that non-
psychiatric physicians are preoccupied with primary medical problems. Despite this 
relative lack of attention, apathy is increasingly recognized as a common behavioural 
syndrome in neurological and psychiatric disorders.134 Because apathy has been 
associated with a number of adverse outcomes – including reduced functional level, 
poor illness outcome, diminshed insight into one’s own behavioural deficits, 
caregiver distress and chronicity – and is potentially treatable,146 it is important that 
physicians understand how to diagnose, treat, and measure the severity of diminshed 
motivation.  
 
The evaluation of apathy should include a detailed history (information from the 
medical record, personell involved in the patient’s care, the medication record, family 
and if possible the patient), clinical examination and neuroimaging to determine the 
presence of potential causes, such as medications (e.g. neuroleptics, SSRIs, beta-
blockers) or underlying medical or neurological disorders (e.g. thyroid dysfunction, 
testosterone deficiency, cerebrovascular disorders, chronic subdural hematoma, 
cerebral tumor, parkinsonism, hydrocephalus, delirium, and malaise of chronic 
illness).178 It is important to include a general mental status examination to reveal 
possible cognitive deficits, which usually require more detailed cognitive testing (i.e. 
neuropsychological evaluation) to determine the type and severity of such. 
Assessment of emotion is especially important to diagnose an underlying depressive 
disorder. Finally, laboratory examination should be undertaken to confirm suspicion 
of other conditions based on the history and clinical examination (blood and 
cerebrovascular fluid analysis, urinanalysis/urine toxicology). If apathy is present, 
validated apathy rating scales 179 should be used to measure the severity of symptoms 
and to monitor responses to treatment over time. 
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Treatment  
Identification of a reversible cause of diminished motivation (e.g. severe 
hypothyroidism, Lyme disease, high-potency typical neuroleptics) is important 
because reversing or arresting the underlying condition may prove sufficient to 
eliminate or significantly reduce the severity of apathetic symptoms. 
 
If the underlying cause of diminshed motivation cannot be fully reversed (e.g. 
neurodegenerative diseases, head trauma), pharmacotherapy should be considered. 
Although little empirical research has been conducted on potential pharmacologic 
treatments for apathy,180 agents that potentiate dopamine release and/or delay 
dopamine reuptake in the CNS are considered the most effective treatment for 
apathy.178, 180 Dopamine agonists, methylphenidate, and atypical antipsychotics have 
all been been demonstrated to reduce apathy in several patient populations.180 In 
addition, acetylcholinesterase inhibitors have been reported to reduce apathy in 
patients with dementia and subjects with traumativ brain injury.180 Patients with 
mixed apathy and depression need special attention. SSRIs have been associated with 
apathy in some patients with depression,174, 175 and frontal lobe dysfunction due to 
alteration of serotonin has been suggested as a possible underlying mechanism. In 
these patients, reducing SSRI-dosage or switching to an selective noradrenaline 
reuptake inhibitor (SNRI) should be considered.161, 181 When apathy is a residual 
feature following successful relief of dysphoric and vegetative symptoms of major 
depression, stimulant therapy with dopamine agonists or methyphenidate should be 
initiated.177, 182 Multimodal integration of socioenvironmental and psychological 
therapies may be benefical to some patients with apathy, and is described in detail 
elsewhere.178, 180 It is especially important to educate caregivers about the symptoms 
of apathy because family members often mistakenly interpret this behaviour as a lack 
of caring and withdrawal from them.183 Finally, ethical considerations regarding 
management of patients with apathy should always be addressed.184 
 53
4. Apathy in Parkinson’s disease 
 
4.1 Apathy rating scales in Parkinson’s disease 
The Movement Disorder Society (MDS) recently commissioned a task force to 
identify and assess the clinimetric properties of scales that have either been validated 
or used in patients with PD.179 Four rating scales specifically designed to assess 
apathy were identified. These include the Apathy Evaluation Scale (AES),136 the 
Apathy Scale (AS),185 the Apathy Inventory (AI),141 and the Lille Apathy Rating 
Scale (LARS).142 In addition, item 4 (motivation/initiative) of the Unified Parkinson’s 
Disease Rating Scale (UPDRS)186 and item 7 (apathy) of the Neuropsychiatric 
Inventory (NPI)140 were included because of its wide use in PD. The scales and items 
were classified according to the total number of required criteria (Table 4.1). 
 
Table 4.1 Classification of apathy scales used in Parkinson’s disease 
Scale Used in 
PD 
Used in PD beyond 
original developers 
Successful clinimetric 
testing in PD 
Classification 
AES X X 0 Suggested 
AS X X X Recommended 
AI X 0 0 Listed 
LARS X 0 X Suggested 
UPDRS item 4 X X X Recommended* 
NPI section 7 X X 0 Suggested 
* As a single item construct, item 4 of the UPDRS cannot be considered a “scale” and is only advised for crude 
screening purposes. Adapted from Leentjens et al.179 
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The AES was developed by Marin and colleagues to assess behavioural, cognitive, 
and emotional domains of apathy. It consists of 18 items that are scored on a four-
point Likert scale (range 1-4), with higher scores indicating more severe apathy. This 
scale has patient-rated, informant-rated, and clinician-rated versions. The AES has 
shown good internal consistency in PD patients, but information on the validity is not 
available. 
 
The AS is an abridged and modified version of AES that was specifically designed 
for patients with PD. It consists of 14 items that are phrased as questions to the 
patient, and the answers are scored on a four-point Likert scale (range 0-3). A 
caregiver rated version is also available. The AS has shown good face validity, 
internal consistency, and interrater and test-retest reliability in PD patients. In a 
sample of 12 PD patients, this scale showed acceptable sensitivity and 100% 
specificity when validated against clinical judgement of apathy. 
 
The AI was designed for global assessment of apathy, and consists of three items 
regarding change in certain behaviours (i.e. emotional blunting, lack of initiative, and 
loss of interest). In case of a positive answer, the change is estimated on a 12-point 
Likert scale. Both patient-rated and informant-based versions exist. If the response to 
the item is yes, two additional questions estimate the frequency and severity of the 
symptom. This scale showed good internal consistency, interrater and test-retest 
reliability in 12 PD patients, but needs better validation to be recommended for use in 
PD. 
 
The Lille Apathy Rating Scale (LARS) was recently developed and designed to 
specifically assess apathy in PD patients with or without dementia. It consists of 33 
items divided into nine domains, and is administered to the patient or an informant as 
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a structured interview. The first three questions are scored on a five-point Likert scale 
(range 0-4), whereas the remaining items are answered yes or no. The total score 
ranges between -36 and +36 points, with positive scores indicating more severe 
apathy. This scale showed good internal consistency, adequate interrater and test-
retest reliability, and good sensitivity and specificity when validated against clinical 
judgement of apathy. 
 
Item 4 (motivation/initiative) of the UPDRS is scored on a five-point Likert scale 
(range 0-4), with increasing scores indicating more severe loss of motivation and/or 
initiative. This item does not include emotional concomitants of apathy. The 
psychometric properties of this item showed moderate interrater reliability, fair test-
retest reliability, and acceptable sensitivity and specificity when a cutoff  2 was 
applied with regard to the diagnosis of apathy based on proposed diagnostic 
criteria.187 
 
The NPI is an informant-based structured interview developed to assess different 
behavioural disturbances, including apathy, in patients with dementia and other 
neurodegenerative disorders. Item 7 includes four screening questions regarding core 
symptoms of apathy. In case of a positive answer, eight additional questions 
regarding different domains of apathy and the total frequency and severity of these 
symptoms are assessed. This item has not been specifically validated in PD patients, 
but has shown good interrater agreement in a small sample of PD patients from the 
community.188 
 
The MDS task force stressed that the validity of apathy scales in PD is limited 
because of the lack of consensus on diagnostic criteria.179 Several unsolved issues 
that require further research were addressed, including confounding influence of 
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depressive symptomatology and cognitive decline on the performance of apathy 
rating scales, the reliability of answers in patient-rated verus informant-rated 
instruments, and assessment of apathy in different phases of motor fluctuations (on 
versus off states). 
 
4.2 Epidemiology 
Several studies of apathy in PD have been reported, with frequency rates ranging 
from 16.5% to 70%, depending upon the instruments used for assessment and by 
whom, different cut-off scores, and the selection of the samples examined (Table 
6.2). In addition, frequency rates are affected by overlapping symptoms with mood 
disorders and variable degree of cognitive impairment in the study population. Most 
samples were not community-based, but rather consisted of hospital-based samples 
recruited from outpatient neurological clinics, implying a considerable risk of 
selection bias.  
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Table 4.2 Frequency of apathy in Parkinson’s disease 
Study Sample N Apathy 
 
Instrument 
(cut-off) 
Depression Dementia Mean 
MMSE 
score 
Control group 
Starkstein 185 Hospital 50 42% AS ( 14) 56% None 25.4 - 28.7 No 
Levy189 
 
Hospital 40 32.5% NPI  ( 1) 55% Unknown 27.9 Other 
degenerative 
brain diseases 
Aarsland188 Community 139 16.5% NPI ( 1) 38% 36 – 42% 25.2 No 
Isella190 Hospital 30 70% 
(43%)* 
AS (>14) 
(AS >16)* 
60% None 
(excluded) 
Unknown Healthy 
Pluck191 Hospital 45 38% AES (>38) 43% 7% 27.8 Osteoarthritis 
Kirsch-
Darrow192 
Hospital 80 51% AS (14) 26% Unknown Unknown Dystonia 
Dujardin193 Hospital 159 32% LARS       
( -16) 
25% 24.5% Unknown Healthy 
Aarsland194 International 
multicentre 
537 54% 
(38%)* 
NPI ( 1) 
(NPI  4)* 
58% 
(21%)* 
100% 19.3 No 
Kulisevsky195 Hospital 1351 48% 
(16%)* 
NPI ( 1) 
(NPI  4)* 
69% 
(30%)* 
None 
(excluded) 
Unknown No 
MMSE = Mini-Mental State Examination; AS = Apathy Scale (self-rated); AES = Apathy Evaluation Scale (clinician-rated); NPI = 
Neuropsychiatric Inventory (apathy item); LARS = Lille Apathy Rating Scale (clinician-rated); UPDRSI4 = Unified Parkinson’s Disease 
rating Scale item 4 (motivation/initiative). *After adjusting cut-off score.  
 
4.3 Relation to demographic, clinical and biochemical    
characteristics 
Although apathy is frequently reported in PD patients with depression,185, 188 several 
studies have shown that apathy may occur in the absence of depression.190, 192 Kirsch-
Darrow and colleagues evaluated 80 subjects with PD and 20 subjects with dystonia, 
and found that half of the PD group had apathy compared with 20% of the dystonia 
group.192 Interestingly, almost 30% in the PD group in contrast to none in the 
dystonia group had apathy in the absence of depression. The authors concluded that 
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apathy is a core feature of PD that can present independently of depression. However, 
the relationship between apathy and cognition was not examined. Other studies have 
demonstrated that apathy is associated with cognitive impairment in PD, especially 
executive dysfunction.185, 188, 191, 193, 196 Starkstein and colleagues reported that PD 
patients with apathy showed more deficits in tasks of verbal memory and time-
dependent tasks,185 whereas others have shown that apathy is mainly determined by 
decreased global cognition.193 Pluck and Brown found significantly higher levels of 
apathy in patients with PD compared to equally disabled osteoarthritic patients, 
suggesting that apathy in PD is more likely a consequence of neurodegeneration than 
psychological reaction or adaption to disability.191 Morover, apathy has been rated 
one of the most distressing behavioural features by caregivers of demented patients 
with PD.194 By contrast, age, education level, motor severity, levodopa dose, and PD 
duration are less likely to be associated with apathy. Although testosterone deficiency 
has been linked to apathy in male patients with PD,197 the role of testosterone in the 
pathophysiology of apathy in these patients is still controversial.198 
 
4.4 The biological basis of apathy in Parkinson’s disease 
The etiopathogenesis of apathy in PD is not clear. Mayeux and colleagues found a 
correlation between the cerebrospinal fluid (CSF) concentration of 3-methoxy-4-
hydroxyphenylglycol (MHPG), the major metabolite of noradrenaline, and cognitive 
measures of bradyphrenia,199 which suggests that bradyphrenia (which is similar to 
the concept of apathy) in PD may be related to dysfunction of catecholaminergic 
pathways and the locus ceruleus.185 A positive influence of levodopa treatment on 
self-reported motivation in PD patients with motor fluctuations has been described,200 
indicating that apathy in PD is at least partly a dopamine-dependent syndrome. The 
cholinergic systems may also have an important modulatory effect upon motivation 
in PD patients, based on the therapeutic benefit of cholinesterase inhibitors for 
treating apathetic behaviour in some PD patients with cognitive impairment and 
dementia.201-203 No MRI changes have been shown to correlate with apathy in PD 
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patients,190 but in a recent study apathy was reported to be inversely correlated with a 
marker of both dopamine and noradrenaline transporter ([11C]RTI-32 binding) in the 
ventral striatum (Remy 2005).204 Together, these data show that the neurobiology of 
apathy in PD is complex and probably involves several different neurotransmitter 
systems which are involved in the signalling between frontal and subcortical areas. 
 
4.5 Treatment strategies 
General strategies 
The first step is to address other differential diagnosis and exclude reversible medical, 
pharmacological, or psychosocial causes of apathy.182 Because neuroleptic drugs and 
SSRIs may cause apathy,163 clinicians should consider whether these drugs can be 
eliminated or given in lower doses. It is important to know that sensory deprivation 
caused by hearing and sight loss, as well as solitary life with low stimulus 
environment, are likely to render the patient apathetic.178 Apathy have a significant 
negative impact on family functioning because family members often mistakenly 
interpret this behaviour as deliberate or insensitive. Non-pharmacological 
interventions include educating patients and caregivers about the symptoms of 
apathy, limiting patient’s responsibility for medication administration, simplification 
of tasks in patients with associated executive dysfunction, occupational therapy to 
explore deficits and maximize functioning, and establish structured environments and 
day programs to maintain a satisfactory activity level.178, 183 
 
Pharmacologic treatment 
The clinical management of apathy is still in its infancy.177 Pharmacologic treatment 
of apathy regardless of the underlying etiology remains anectdotal and have only 
been tested in open trials or reported as case studies. In general, depressed patients 
with prominent apathetic features may benefit from a more stimulating 
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antidepressant, such as bupropion.182, 205 In contrast, SSRIs do not seem to improve 
apathy, and may even lead to worsening of apathetic features.174 At present, 
dopamine receptor agonists are regarded as the most effective treatment for apathy in 
neurological disorders.177 In PD, levodopa has shown some positive but incomplete 
effect in patients with motor fluctuations.200 If apathy persists when motor symptoms 
are adequately treated, higher doses of the dopaminergic medications or introduction 
of a dopamine agonists should be considered.177 A recent meta-analysis of seven 
randomized controlled trials suggested that pramipexole, a potent dopamine D2 
agonist with preference for D3 receptors, had a beneficial effect on mood and 
motivational symptoms in PD patients who did not have major depressive disorder.206 
However, the clinical value of pramipexole in the treatment of apathetic syndromes 
requires further investigation. In non-PD patients, older subjects with apathy may 
benefit from psychostimulants such as methylphenidate and dextroamphetamine.207 
To date, methylphenidate has only been described to be beneficial in a single case 
report of an older patient with PD.208 Placebo-controlled studies with cholinesterase 
inhibitors have shown promising results on behavioural syndromes, including apathy, 
in PD with cognitive impairment and dementia.201-203  
 
Effects of deep brain stimulation (DBS) on apathy 
Several studies have reported changes in mood and apathy after DBS surgery in PD. 
In a comprehensive review of apathy following STN DBS surgery,209 four studies 
reported increased apathy score from pre-surgery to post-surgery, two reports did not 
find any change, and one report of reduction in acute apathy when stimulators were 
switched from off to on. None of these reports found a significant reduction in mean 
apathy scores over time, leading to the conclusion that apathy is not improved by 
STN DBS surgery.   
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4.6 Course and prognosis 
No studies have examined the longitudinal course of apathy in PD. Because the risk 
of developing dementia is up to six-fold higher in PD than in non-PD subjects,78 and 
the cumulative prevalence of dementia increases with age and duration of PD,210 
higher frequency rates of apathy are expected in more advanced stages of PD 
compared with early disease.  
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5. Aims of the thesis  
 
The primary objectives of this thesis were to describe and achieve a better 
understanding of apathy as a neuropsychiatric disorder in community-based patients 
with PD across different stages of disease. To obtain this information we: 
 
 validated the motivation/initiative item of UPDRS part I as a screening and 
diagnostic instrument for apathy in patients with PD (paper I). 
 examined the prevalence and clinical correlates of apathy in a large population-
based sample of patients with PD, and explored whether apathy may present as a 
primary behavioural disturbance independent from depression and cognitive 
impairment, or the direct physiologic effects of psychotropic medication (paper 
II). 
 investigated the occurrence and risk for apathy with emphasis on motor, 
depressive and cognitive symptoms in a longitudinal cohort of patients with PD 
over 4 years (paper III). 
 examined the frequency and clinical correlates of apathy in an incidence cohort of 
patients with untreated PD (paper IV). 
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6. METHODS 
 
6.1 Patient selection and follow-up 
In paper I-III, patients were recruited from a population-based prevalence study of 
PD conducted in Rogaland County, Western Norway between September 1992 and 
May 1993.211 In an attempt to achieve complete case ascertainment in the study area 
comprising 220,000 inhabitants from nine municipalities, all available health care 
sources were used, including an extensive search of all potential candidates in 
hospital files and information gathered from general practioners (GPs), nursing 
homes, district nurses, health workers and the Rogaland Parkinson’s Disease Society. 
About 400 candidates were interviewed and examined by a neurologist with special 
interest in movement disorders at two consecutive visits held within 1 month in the 
study period, of whom 245 fulfilled a diagnosis of PD according to published 
diagnostic criteria.212 The crude prevalence rate was 110.9 per 100,000 inhabitants on 
January 1, 1993. Of the 245 patients initially diagnosed with PD according to 
published criteria, three patients died before the examination program was completed, 
two refused to participate, sufficient data was missing in one, and seven were 
rediagnosed as not having PD. Thus, 232 patients were included in the prevalence 
study of apathy in paper II. These patients were followed prospectively and the 
survivors were invited to participate in a follow-up study in 1997 and 2001. A total of 
139 were eligible for examination in 1997, and in 2001 we included 79 patients to 
participate in a 4-year longitudinal study of apathy (paper III). Fifty-eight patients at 
8-years follow-up in 2001 were eligible for validation of the UPDRS apathy item in 
paper I.  
 
The Norwegian ParkWest study is a multicentre population-based prospective 
longitudinal cohort study of the incidence, neurobiology and prognosis of PD in 
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Western and Southern Norway.12 The study area is constituted by the four counties of 
Sogn and Fjordane, Hordaland, Rogaland and Aust-Agder, comprising a total 
population of more than one million inhabitants. All neurological services in the 
study area participated in the project to include all cases with incident PD during a 22 
months period between November 2004 and August 2006. Multiple case finding 
strategies were employd: 1) Hand-screening of all referral letters to the participating 
study centres to identify symptoms possibly representing incident parkinsonism, 2) 
notification about the study to all other hospital departments and 3) GPs in the study 
area, including those consulting nursing homes, geriatric care centres and other 
institutions for persons of older age, 4) electronic screening of inpatient and 
outpatient hospital databases for patients being diagnosed with incident PD during 
the inclusion period and for three months after to capture delays in coding, and 5) an 
electronic population screening by linkage to GPs electronic medical record systems. 
Of totally 603 subjects screened, 265 fulfilled strict diagnostic research criteria of 
PD55 after an average of 28 months prospective follow-up. The crude incidence rate 
was 13.7 per 100,000 person years.12 A cohort of 212 subjects consented in long-term 
study participation, 201 of whom were ever drug-naïve and therefore eligible for 
inclusion in paper IV. None of the 201 patients had a history of markedly cognitive 
decline preceding motor symptoms or in the first year of the disease. 
 
6.2 Control subjects (paper IV) 
Paper IV also included 201 control subjects recruited from friends and spouses of 
patients with PD, or unrelated persons from social clubs for the elderly, in the study 
area between November 2004 and April 2007. To be included, control individuals 
had to be free from parkinsonism but other movement disorders besides 
parkinsonism, neurological disorders, or major medical or psychiatric disorders were 
not considered to be exclusion criteria. A subgroup of 171 subjects who provided the 
best possible match to age and sex distribution and years of education was included 
for group comparisons.  
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6.3 Diagnosis of PD 
In order to achieve high sensitivity and specificity in case ascertainment, a new 
diagnostic classification was used to diagnose PD at different levels of clinical 
confidence in paper I-III:212 
 
Clinical definite PD 
The patient presents with resting tremor and at least two of the following signs: 
bradykinesia, rigidity, or postural abnormality. Additional mandatory features are 
unilateral onset and asymmetrical development, as well as good to excellent response 
to dopaminergic agents. Neither atypical signs and symptoms nor significant changes 
on CT or MRI other than mild diffuse cortical atrophy or mild hypertensive 
periventricular foci are accepted. 
 
Clinical probable PD 
The patient must present at least two of the four cardinal signs, but one of the 
following atypical features is allowed: early mild dementia or clinically relevant 
autonomic failure, symmetrical disease presentation, only moderate response to 
dopaminergic treatment, atypical signs or symptoms indicating another parkinsonian 
disorder, or significant brain changes on CT or MRI. 
 
Clinical possible PD 
The patient must present at least two of the four cardinal signs and response to 
dopaminergic agents should be at least moderate. Mild to moderate dementia and 
autonomic failure may be allowed. Other atypical signs or symptoms indicating 
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another parkinsonian disorder, or significant brain changes on CT or MRI, are not 
accepted. 
 
In paper IV, we applied recently proposed criteria by Gelb and colleagues to diagnose 
PD at three levels of confidence:55 
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6.3 Clinical assessment tools 
6.3.1 Assessment of parkinsonism and disability 
Several established clinical instruments have been developed to measure the severity 
and progression of motor symptoms and disability in PD: 
 
The UPDRS is the most widely known rating tool in PD.186 It was developed in 1987 
by an international group of movement disorder specialists, and has been shown to be 
both reliable and valid in measuring the longitudinal course of the disease. The 
UPDRS evaluates four components: Mentation, behaviour, and mood (part I), 
activities of daily living (part II), motor examination (part III), and complications of 
therapy (part IV). Each item in part I-III is scored on a five-point Likert scale (0 
indicates normal functioning and 4 indicates maximal severity). Recently, the 
UPDRS has undergone major revisions to better capture the nonmotor problems 
experienced by patients with PD.213 
 
Another widely used assessment instrument in PD is the Hoehn and Yahr staging 
scale.119 This scale was introduced in 1967 and intends to measure the development 
of the disease, including impairment and disability of movement, balance and gait. 
Stages of disease progression range from 0 (no signs of PD) to 5 (parkinsonian 
symptoms on both sides and not able to walk). Nonmotor problems are not evaluated 
by the scale. 
 
The Schwab and England scale is commonly used to assess disability in PD 
patients.214 It assesses speed and independency in performing activities of daily 
living, and ranges from 100% (completely independent, essentially normal) to 0% 
(bedridden, vegetative dysfunction). 
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In paper III, total UPDRS motor score (range 0-108) was divided into six motor 
domains (speech, facial expression, tremor, rigidity, bradykinesia, and axial 
impairment) based on the cardinal clinical manifestations of PD.81  These six motor 
domains were grouped into two subscores that represented predominantly 
dopaminergic (subscore A: tremor, rigidity, bradykinesia, and facial expression; 
range 0-88) and nondopaminergic (subscore B: speech and axial impairment; range 0-
20) deficiencies.81 
 
6.4.2 Assessment of apathy 
Several scales have been designed to assess apathy and have been validated or used 
in studies with PD patients,179 see section 4.1. Two different scales were applied in 
this thesis. 
 
The AS is a 14-item abridged and modified version of the AES developed by Marin 
and colleagues in 1991. It was specifically developed for patients with PD, because 
the AES was considered too demanding. Questions are answered on a four-point 
Likert scale (0 = a lot, 1 = some, 2 = slightly, and 4 = not at all) and apathy scores 
range from 0 to 42, with higher scores indicating more severe apathy. The reliability 
and validity of the original, patient-based version of AS has been established,185 but a 
caregiver-rated version is available as well. An international committee with 
extensive expertise in the area of mood and motivational symptoms in PD have 
recently assessed the clinimetric properties of the AS. This scale was recommended 
to screen and to assess the severity of apathy in PD patients.179 In paper I, the AS was 
used to generate diagnosis of apathy by means of a specific scheme suggested by 
Starkstein and colleagues.215, 216 Briefly, apathy was diagnosed whenever patients had 
poor or no motivation (a score of  2 on item 7), interest (a score of  2 on item 1 or 
2), effort (a score of  2 on item 4 or 9), and had feelings of indifference or lack of 
emotions most or all of the time (a score of  2 on item 10 or 13). This diagnostic 
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scheme has recently showed high sensitivity and specificity for clinically diagnosed 
apathy in a large series of PD patients.217 
 
The NPI was designed to assess psychopathology in dementia and other 
neurodegenerative disorders. It includes an apathy subsection where the informant is 
asked four screening questions regarding loss of interest, lack of motivation, poor 
engagement and indifference. A positive endorsement of any of those items triggers a 
subset of eight subquestions to explore the symptoms and severity of apathy. 
Frequency is rated on a 1 to 4 scale, and severity on a 1 to 3 scale. In study III, 
subjects were considered apathetic if they had a composite apathy score (severity 
multiplied by frequency) of  4, as recently recommended in PDD.218 In study IV, 
however, patients with possible dementia were excluded. Therefore, a different 
approach was applied to diagnose subjects (patients with PD and control individuals) 
with apathy. A diagnosis of apathy was considered if subjects had an NPI apathy 
score of  1. We also checked that all these subjects fulfilled the recently proposed 
consensus criteria for apathy.143 For this purpose, we verified that the NPI apathy 
subquestions included at least one symptom in at least two of the three apathy 
domains: (1) diminished goal-directed behaviour (Does the patient seem less 
spontaneous and less active than usual? Is the patient less likely to initiate a 
conversation? Does the patient contribute less to household chores (not due to motor 
severity)? Does the patient show any other signs that he/she doesn’t care about doing 
new things?); (2) diminished goal-directed cognitive activity (Does the patient seem 
less interested in the activities and plans of others? Has the patient lost interest in 
friends and family members?); and (3) diminished emotion (Is the patient less 
affectionate or lacking in emotions when compared to his/her usual self? Is the 
patient less enthusiastic about his/her usual interests?). High interrater reliability of 
the NPI apathy subsection has been demonstrated in PD.188 A later version of the 
NPI219 was also used to measure emotional distress experienced by the caregiver 
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engendered by the apathetic behaviour (level of distress: not at all = 1, minimal = 2, 
moderate = 3, severe = 4, very severe or extreme distress = 5).  
 
 
6.4.3 Assessment of depression 
Severity of depressive symptoms was assessed using the MADRS.220 This 10-item 
scale is based on a clinical interview of the patient, where the observer decides the 
score on each item on a seven-point scale (ranging from 0 to 6 points). The items are 
rated with regards on the state of the patient over the past week. This rating scale 
covers all the DSM-IV criteria of a major depressive episode, except psychomotor 
retardation/agitation and neurovegetative symptoms such as hypersomnia and 
increased appetite. It was originally designed to measure change in severity of 
depressive symptoms during antidepressant clinical trials, and has been shown to be 
sensitive, reliable and valid as a measure instrument of depression. Leentjens and 
colleagues found the MADRS to be an adequate instrument for measuring depressive 
symptoms and for diagnosing a major depressive disorder in PD.221 In study II and 
III, major depression was diagnosed by administering a semistructured interview 
according to the DSM-III-R. 
 
6.4.4 Assessment of cognitive impairment and dementia 
The MMSE is one of the most widely used clinical instruments for quickly detecting 
cognitive impairment.222 It consists of 30 items assessing orientation, short-term 
memory (retention), attention, short-term memory (recall), and language. The MMSE 
can be used to screen for cognitive impairment and assess its severity at a given time 
point, monitor the course of cognitive changes over time, and to document the 
response to treatment. It provides a total score indicating the cognitive function of a 
subject. Although the MMSE has been shown to be both a reliable and valid measure 
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of cognitive impairment, it is relatively insensitive to executive dysfunction218 and is 
influenced by the effects of age and level of education.223 
 
In paper II, dementia was diagnosed according to DSM-III-R criteria based on a 
semistructured interview with the caregiver and scores on the MMSE, Gottfries-
Bråne-Steen (GBS) scale,224 and item 1 (intellectual impairment) of UPDRS part I. 
The GBS rates severity of dementia and provides a profile of the symptoms of 
dementia by estimating motor, intellectual, emotional, and other characteristic 
features of dementia in four subscales. Each item is scored on a clearly defined 
seven-point scale (0 indicates normal functioning and 6 indicates maximal severity). 
The rating is based on observation of the patient and an interview with the patient and 
a caregiver. The UPDRS intellectual impairment item rates memory, orientation, 
problem solving, function at home, and personal care. The scores ranges from 0 (no 
impairment) to 4 (severe impairment). 
 
A more extensive cognitive assessment battery was performed to diagnose dementia 
in paper III, including the MMSE, Mattis Dementia Rating Scale (Mattis DRS),225 
and selected neuropsychological tests that were thought to be independent of motor 
abilities. The Mattis DRS is a widely used dementia screening instrument that is 
divided into five subscales measuring attention, initiation, construction, 
conceptualization, and memory. Scores range from 0 (maximal severity) to 144 
(normal cognitive function). The scale has been shown to robustly and accurately 
distinguish between cortical and subcortical dementia profiles.226 Three 
neuropsychological tests were included. The multiple choice version of the Benton 
Visual Retention Test227 consists of 15 items presented for 10 seconds, where 
subjects are supposed to recognize one or more designs that they have seen before. 
This test assesses short-time visual memory. The Judgement of Line Orientation 
Test228 consists of 30 items, each showing a different pair of angled lines to be 
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matched with display cards, and was designed to assess visual/spatial abilities. The 
Stroop test229 was used to assess selective attention/executive functions. We used a 
version which consists of three cards: subjects name the colour of coloured patches 
(1st card), read printed words (2nd card), and read printed colour names in which the 
ink used for printing is a colour different from the colour designed by the printed 
name (3rd card). Both the time needed to complete each card and the number of errors 
was recorded. For MMSE and MDRS, age- and education-based cut-off scores were 
used. Dementia was diagnosed according DSM-III-R criteria based on the clinical 
interview, cognitive rating scales, and neuropsychological tests. 
 
In early PD, cognitive dysfunction may be subtle and therefore not assessable by 
common clinical rating instruments. To detect early cognitive changes in paper IV, a 
battery of neuropsychological tests not or only minimally affected by motor 
performance was chosen to assess four cognitive domains in PD. Verbal memory was 
evaluated using the California Verbal Learning Test II (CVLT-II),230 which consists 
of 16 words which were read five times, and after each time the patient was asked to 
recall as many words as possible. Total immediate recall (sum of trials 1–5), short-
delay, and long-delay free recall (after 20 minutes) scores were included in the 
analyses. Attention and executive functions were assessed with the semantic verbal 
fluency231 and interference part of the Stroop test.232 In the semantic verbal fluency 
test patients are asked to generate as many names of animals as possible within 1 
minute. The interference part of the Stroop test is performed by asking the patient to 
tell the colour of the word (3rd card). Psychomotor speed was examined using the sum 
of words produced during the colour (1st card) and the word (2nd card) conditions 
from the Stroop test. Visuospatial abilities were assessed using the Silhouettes and 
Cube subtests from the Visual Object and Space Perception Battery (VOSP).233 In the 
Silhouette test, the subject is asked to identify the outline of 30 objects which are 
rotated through varying degrees from the lateral axis. The cube tests consist of 10 
representations of a three dimensional arrangement of square bricks, and the subject 
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is asked to count the number of bricks. Dementia associated with PD was diagnosed 
using recently proposed consensus criteria as a guide,74 based on neuropsychological 
tesing, MMSE, and the Informant Questionnaire on Cognitive decline in the elderly 
(IQCode).234 The IQCode is a standardized measure with proven psychometric 
properties, and a cut-off which was based on the sample closest in composition to our 
PD population was chosen.70  
 
6.4.5 Statistical analysis 
In paper I, the Spearman correlation coefficient was used to calculate the association 
between different measures of apathy and depressive symptoms. A receiver operating 
characteristic (ROC) curve was employed to analyse sensitivity and specificity for the 
UPDRS apathy item, and to select an optimal cut-off score for identifying apathy. 
 
In paper II-IV, Mann-Whitney tests were used for comparisons of medians for 
continuous variables and differences in proportions of categorical variables were 
analyzed by 2 tests or Fisher’s exact tests where an expected cell frequency was less 
than five. When comparing more than two groups, Kruskal-Wallis tests were used for 
continuous variables and linear-by-linear association tests for categorical variables. 
Binary logistic regression analyses with forward stepping (likelihood ratio method) 
were applied to assess variables that were independent correlates of apathy. In paper 
II, effect size estimates were applied to measure which factors contributed most 
strongly to the presence of apathy. Finally, in paper IV we used Wilcoxon signed 
rank tests to compare differences between paired groups over time. 
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7. Results 
 
Paper I 
We examined the validity of the motivation/initiative item of the UPDRS part I as a 
screening and diagnostic measure for apathy in PD, and found that a cut-off score of 
2 was adequate to screen for apathy with questionable diagnostic quality, whereas a 
cut-off score of 4 had high diagnostic accuracy at the cost of unacceptable low 
sensitivity. 
 
Paper II 
Apathy was diagnosed in 38% of 232 patients with PD. In 11% of the total sample 
apathy coexisted with depression and dementia, whereas 10% had apathy and 
depression without dementia, 6.5% apathy and dementia without depression, and 9% 
were apathetic without dementia or depression (data missing in 1.5% patients). 
Apathy was significantly associated with higher depression scores, lower cognitive 
functioning, and more severe motor symptoms. When excluding patients with 
depression, dementia, cognitive impairment with no dementia (population-based age- 
and education-corrected norms for the MMSE), and those using psychotropic 
medication, 5% of the 232 patients remained apathetic. 
 
Paper III 
Of the 79 patients with PD examined in 1997 and 2001, 29 patients (36.7%) had 
never apathy, 11 (13.9%) had persistent apathy, and further 39 (49.4%) developed 
apathy during follow-up. At follow-up, patients with apathy were more frequently 
depressed and demented than never-apathetic patients. Dementia at baseline and a 
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more rapid decline in speech and axial impairment during follow-up were 
independent risk factors for incident apathy. 
 
Paper IV 
Apathy was diagnosed in 22.9% of 175 nondemented, drug-naïve patients with 
incident PD, of whom 37.5% had significant depressive symptoms, whereas none of 
the 165 matched control subjects were apathetic. Apathy was significantly associated 
with male gender, higher depression scores and more severe motor symptoms, but 
was not associated with greater cognitive impairment. When excluding patients with 
significant depressive symptoms, apathy remained significantly associated with 
motor severity. Approximately 50% of the caregivers of patients with apathy reported 
the apathetic behaviour to be at least moderately distressing. 
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8. Discussion 
 
8.1 Methodological considerations 
Epidemiological research seeks to provide information about the distribution and size 
of disease problems, and their associated risk factors in the general population. In 
particular, epidemiological data may help to identify aetiological factors in the 
pathogenesis of diseases and to provide data essential for identifying at risk-groups 
and planning of services for the prevention, control and treatment of disease. The 
quality of epidemiological research depends on several methodological aspects which 
are necessary to obtain reliable and reproducible data. 
 
The diagnosis of PD is still based on disease history and clinical examination, as no 
exact test is currently available to provide a definite diagnosis. In addition, PD is 
characterized by considerable clinical heterogeneity and symptoms may overlap with 
both symptomatic parkinsonism (e.g. drug-induced, vascular disease, post-infectious) 
and parkinsonism caused by other neurodegenerative disorders (e.g. MSA, PSP, 
dementia with Lewy bodies) in early stages. Therefore, the use of careful diagnostic 
criteria is essential to provide high sensitivity and specificity for the diagnosis of PD. 
Studies from several brain banks in the early 1990s reported poor precision of the 
clinical diagnosis of PD.235, 236 Even though patients were diagnosed by neurologists, 
only 76% had Lewy bodies in the brain at autopsy. In an effort to achieve both high 
sensitivity and specificity, we applied a new diagnostic classification in paper I-III to 
diagnose patients with PD at different levels of confidence.211, 212 Furthermore, 
patients were reevaluated after four and eight years to possibly revise the clinical 
diagnosis of PD in those who had developed atypical signs and symptoms during the 
course of disease. As a result, less than 3% were rediagnosed as not suffering from 
PD during follow-up. Of the 22 patients who have been autopsied so far, all fulfilled 
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neuropathological criteria of PD.237 In paper IV, which is part of the Norwegian 
ParkWest study,12 patients were diagnosed according to widely acknowledged criteria 
of PD55 after an average of 28 months prospective follow-up. Like the diagnostic 
criteria used in paper I-III, the new criteria differentiated three levels of diagnostic 
confidence. 
 
An unfavourable trend in epidemiological studies is to include patients based on 
retrospective review of medical records, which are likely to represent information 
from highly selected subpopulations with more advanced disease. In addition, cohort 
studies often include selected groups, such as PD patients treated at highly 
specialized movement disorder clinics, who may not be representative for the disease 
population in a specific geographic area. To achieve a high degree of case 
ascertainment in Rogaland County, patients in paper I-III were recruited through 
search in hospital files and information gathered from the local branch of the 
Norwegian Parkinson’s disease Society, GPs, nursinghomes, district nurses, and 
health workers in the study area. In paper IV, multiple sources of case ascertainment 
were used to establish a representative cohort of patients with incident PD from the 
four counties of Sogn and Fjordane, Hordaland, Rogaland and Aust-Agder. The 
following strategies were employed for case identification: 1) Screening of all referral 
letters to the participating study centres for symptoms possibly representing incident 
parkinsonism, 2) notification of all other hospital departments and all GPs in the 
study area, 3) electronic screening of inpatient and outpatient hospital databases for 
patients being diagnosed with PD for the first time during the screening period and 
for 3 months after to capture delays in coding, and 4) an electronic population 
screening of 43,716 individuals by linkage to GPs’ electronic medical record systems 
dated back to 1 year before study start.  
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The assessment of all participants included semistructured interviews on 
demographic variables, medical history and medication. Standardized and validated 
instruments for assessment of parkinsonism and disability, depression, cognitive 
impairment and dementia were applied by trained and experienced staff at each study 
visit. These are thoroughly described in the methodology chapter of this thesis. 
However, the assessment of apathy needs further discussion. To date, none of the 
apathy rating instruments currently available have been validated against recently 
proposed consensus criteria for the clinical diagnosis of apathy in neuropsychiatric 
disorders.143 Due to the lack of validated tools for assessment of apathy at baseline in 
the prevalence study of PD in Rogaland County, we attempted to validate the UPDRS 
apathy item against a specific diagnostic scheme215, 216 in patients from the same 
study at 8-years follow-up. We found that the optimal cut-off score for a diagnosis of 
apathy was  2 (paper I), which we further applied to examine the prevalence and 
clinical correlates of apathy at baseline (paper II). In Paper III, apathy was diagnosed 
by using a composite NPI apathy subscore of  4, which has recently been 
recommended in PDD.218 This is reasonable, given that more than 60% of patients 
were demented at follow-up. In Paper IV, subjects with possible dementia were 
excluded and apathy diagnosed whenever participants had an NPI apathy subscore of 
 1 and fulfilled the apathy domain section of the recently proposed consensus 
criteria for apathy. A major limitation of this thesis is the use of different apathy 
rating instruments and cut-off scores rather than a structured psychiatric interview to 
diagnose apathy. Consequently, it is possible that subjects with apathy might have 
been left undetected, or vice versa, that some participants were wrongly diagnosed 
with apathy. However, the fact that our classifications of apathy were strongly 
associated with depression and cognitive dysfunction, as shown in most other studies 
of apathy in PD,179 strengthen our findings as reliable.  
 
Finally, the use of adequate statistical methods is important to produce reliable data. 
In paper I, we applied a ROC curve to select an optimal cut-off score for identifying 
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apathy. In paper II-IV, we used binary logistic regression models for correlated data. 
These allowed the assessment of several variables to identify independent correlates 
of apathy. 
 
8.2 Findings 
8.2.1 Validity of the UPDRS apathy item in PD 
The UPDRS was originally developed as a core assessment tool to evaluate change in 
PD signs and symptoms over time. Although this instrument mainly focuses on motor 
aspects of PD (part II-IV), part I consists of four items assessing intellectual 
impairment, thought disorder, depression, and motivation/initiative, which is meant to 
be used as a screening for dementia, psychosis, depression, and apathy, respectively. 
The motivation/intitative item is rated on a five-point Likert scale and scores include 
the following: 0 = Normal, 1 = less assertive than usual; more passive, 2 = loss of 
initiative or disinterest in elective (nonroutine) activities, 3 = loss of initiative or 
disinterest in day-to-day (routine) activities, and 4 = withdrawn; complete loss of 
motivation.  
 
Although the motivation/initiative item has previously been applied as an assessment 
tool to diagnose apathy in patients with PD,238, 239 the validity of this item was 
unknown. Therefore, in our first study (paper I) we aimed to examine its properties as 
a screening and diagnostic instrument for apathy in a cohort of patients with moderate 
to advanced PD who were given the AS as part of a follow-up examination in an 
ongoing prospective longitudinal study of PD in Rogaland County, Western Norway. 
To provide a gold standard for the diagnosis of apathy, we applied a specific 
diagnostic scheme215, 216 which converted AS core items into a version of currently 
proposed criteria.137 The main finding was that a cut-off score of  2 on the 
motivation/initiative item was adequate for apathy screening at the cost of 
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questionable diagnostic accuracy, whereas a cut-off score of  4 had high diagnostic 
quality with poor sensitivity. Based on our finding, we suggested to use a cut-off 
score of  2 as a screening tool, and then apply AS-derived or other criteria for a 
more accurate diagnosis. Methodological limitations of this study include the lack of 
a gold standard of established diagnostic criteria and validated ad-hoc scales for 
apathy, a relatively high proportion of patients with missing data due to severe 
dementia or refusal to participate, which could have biased the frequency of apathy to 
a lower rate, and the recruitment of patients after 8-years follow-up, which may have 
led to a sample of more severe cases. At the time of submission of our study, 
Starkstein and Merello conducted a validation study of the UPDRS part I using 
similar methods.187 Their patients were younger (mean age 65.9 vs. 74.2 years), had 
shorter duration of illness (mean duration 5.9 vs. 9.3 years), were not biased toward 
more severe cases (Hoehn-Yahr stage  III: 53% vs. 67%), but were generally similar 
regarding global cognitive functions (mean MMSE score 24.4 vs. 23.0). As in our 
study, they concluded that a motivation/initiative cut-off of 2 is adequate for 
screening, but not for diagnostic purposes in PD. These findings have recently been 
supported by Gallagher and colleagues using another apathy rating scale,240 whereas 
Kirsch-Darrow and colleagues suggested caution when screening for apathy with the 
motivation/initiative item due to its poor sensitivity in relation to an AS cut-off score 
of  14.241 Although the majority of validity studies supported our finding, it is 
necessary to re-examine the operating characteristics of the AS and 
motivation/initiative item with newly proposed consensus criteria for apathy as a 
guide. Of notice, the AS-derived diagnostic scheme has recently been validated in PD 
patients against the opinion of an experienced neuropsychiatrist blind to psychiatric 
findings. In this study,217 Starkstein and colleagues reported high sensitivity (82%) 
and specificity (92%) for clinically diagnosed apathy.  
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8.2.2 Frequency of apathy in early versus late PD 
Prevalence rates of apathy in PD vary widely across studies, ranging from 16.5% to 
70%. Possible reasons for this variation include the selection of the population 
studied and the way the diagnosis is established. For example, the lowest prevalence 
is reported in a follow-up study of 139 community-based patients from Rogaland 
County, Western Norway.188 These patients were on average 74 years old, and the 
mean duration of PD was nearly 13 years with 64% of the population in Hoehn and 
Yahr stage III or above. Fifty patients, 36% of the sample, met the DSM-III-R criteria 
for dementia. Using an NPI subscore of  1, Aarsland and colleagues found that 
16.5% of the patients were apathetic and 38% depressed. In contrast, the highest 
prevalence rate is reported in a hospital-based study of 30 patients from Italy.190 The 
mean age of the sample was 65 years, mean disease duration 5 years, and the mean 
UPDRS motor score was 32. Patients with severe dementia were excluded. When 
applying the self-rated AS with a cut-off score of > 14, 70% of the patients appeared 
apathetic. After adjusting the cut-off score to > 16, the prevalence declined to 43%. 
Eighteen patients, 60% of the sample, were depressed according to the Geriatric 
Depression Rating Scale.242 
 
To explore changes in the frequency of apathy in early versus late PD, we examined 
two different population-based samples using the diagnostic procedures described in 
the methodology chapter of this thesis. In Paper IV, we examined 175 nondemented, 
drug-naïve patients with newly diagnosed PD and 165 matched control subjects from 
the Norwegian ParkWest study. Apathy was found in 23% of the PD patients, of 
whom 37.5% had significant depressive symptoms, whereas none of the control 
subjects were apathetic. In paper II and III, patients were derived from the prevalence 
study of PD in Rogaland County. At baseline, apathy was diagnosed in 38% of the 
232 patients (paper II). Patients were on average 73.5 years old, mean duration of 
disease 9 years, and the mean UPDRS motor score was 28.5. Twenty-one patients, 
9% of the population, were apathetic without dementia or depression. After excluding 
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patients with cognitive impairment without dementia and those using psychotropic 
medication, only 5% remained with “pure” apathy. At 8-years follow-up, or a mean 
disease duration of 17 years, 79 patients were available for examination (paper IV). 
The mean UPDRS motor score ranged from 51 to 61 in those who had developed and 
those with persistent apathy during the last 4 years, respectively. We found that 63% 
of the sample were apathetic, of whom 32% were depressed and 88% demented. 
These observations demonstrate that apathy increases with the duration and 
progression of PD, especially as patients get demented. Obviously, major limitations 
are collection of data from two different populations, long time intervals between 
study visits, and different diagnostic procedures of apathy. Therefore, caution must 
be taken when interpreting our findings.  
 
8.2.3 Clinical correlates of apathy in PD 
In contrast to varying results regarding the frequency of apathy in PD, studies of 
clinical correlates have been relatively concurrent. Most studies report an association 
of apathy with depression and more severe cognitive symptoms or dementia. In paper 
II, we replicated these findings in a large community-based study of apathy in PD, 
showing that apathy was associated with higher depression scores and lower 
cognitive functioning. Further analysis showed that the MADRS dysphoric/apathy 
factor primarily contributed to the dependency between apathy and MADRS scores. 
Similar findings have been reported by others (ref).193, 243, 244 Furthermore, apathy 
coexisted with depression in 21 % and with dementia in 17.5% of the total sample. 
Only 9% with neither depression nor dementia had apathy. Because apathy may be a 
residual symptom of a depressive episode or side-effect of antidepressant or 
antipsychotic drugs, we further excluded those using psychotropic medication. Five 
percent remained apathetic, which indicates that apathy rarely presents as an 
independent syndrome in patients with mild to moderate PD. This finding has been 
supported by two other studies.193, 217 Dujardin and colleagues found a strong 
association between depression, dementia and apathy in PD patients with varying 
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degrees of disease severity.193 Recently, Starkstein and colleagues examined patients 
with mostly mild to moderate PD, and reported that 83% of those with apathy had 
comorbid depression and 56% had dementia.217 In contrast, when examining a large 
multicentre-based population of untreated, nondemented patients with newly 
diagnosed PD, we found significant association between apathy and higher 
depression scores but not greater cognitive impairment (paper IV). Apathy was 
diagnosed in 23% patients with PD, of whom only 37.5% had significant depressive 
symptoms. All together, these findings suggest that the proportion of PD patients 
with an isolated syndrome of apathy is higher in early versus late PD, probably 
reflecting different profiles of neurotransmitter changes. 
 
Previous studies have not reported any differences between PD patients with or 
without apathy regarding demographic variables, duration of illness, and motor 
severity, suggesting that apathy may not be simply related to progression of disease. 
In paper II and IV, however, we reported a significant association between apathy 
and severity of motor symptoms, indicating a common underlying pathophysiological 
mechanism. One hypothesis is that apathy in PD patients is a marker of more severe 
dopaminergic dysfunction in both nigrostriatal and mesolimbic pathways, and loss of 
direct dopaminergic projections from the brainstem ventral tegmental area to motor 
basal ganglia connections is a possible explanation. However, further studies are 
needed to explore this hypothesis. In paper IV, we also found a significant association 
between apathy and male gender. Low testosterone levels in elderly men with PD 
have been linked to symptoms of apathy,197 but the role of testosterone in the 
pathophysiology of apathy is still controversial.198 An alternative, although 
speculative, explanation could simply be that female caregivers are more prone to 
report behavioural deficits than male caregivers are. Finally, in the same study apathy 
contributed to considerable distress among 50% of the caregivers, which underscores 
the importance of educating family members about the symptoms of apathy in early 
PD.  
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8.2.4 Longitudinal course and risk factors of apathy in PD  
Previous studies of apathy in PD have only been cross-sectional. However, there is a 
need for studies exploring the development of apathy in PD over time, and several 
important questions need to be answered: What is the longitudinal incidence and 
prevalence of apathy in PD? Which demographic and clinical variables are related to 
apathy over time and across different stages of PD? Is apathy a persistent problem 
over time in patients with PD? Is persistent apathy a risk factor for more severe motor 
symptoms, depression or cognitive dysfunction in PD? What factors predict incident 
apathy in PD? In paper III, we followed a cohort of patients with PD over four years, 
and found that 37% never had apathy, 14% had persistent apathy, and further 49% 
developed apathy during follow-up. Patients with apathy were more frequently 
depressed and demented at follow-up compared to never-apathetic patients. Persistent 
apathy was not associated with incident depression or dementia at follow-up. 
However, low statistical power due to relatively few patients with incident apathy (n 
= 11) may perhaps explain this finding, and further studies including more patients 
are needed to fully examine this question. Nevertheless, we found that dementia at 
baseline and a more rapid decline in speech and axial impairment during follow-up 
contributed significantly to the risk of incident apathy. This finding indicates that 
progression of motor signs predominantly mediated by non-dopaminergic systems 
may be a useful preclinical marker for incident apathy in PD. Further research in 
larger groups of patients with early PD and with more frequent evaluations over time 
is necessary to identify factors that may predict apathy at an earlier stage of the 
disease.  
 
8.3 Implications for clinical practice and future research 
Apathy has long been living in the shadow of depression and dementia. In fact, some 
would argue that apathy is a mood disorder or part of a dysexecutive syndrome. 
However, recent consensus criteria for apathy now consider it to be an independent 
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neuropsychiatric syndrome characterized by loss of or diminished motivation.143 The 
results of the present thesis confirm previous studies showing that apathy is both 
common and may exist independently of significant depressive symptoms or severe 
cognitive dysfunction in PD. One of the most important findings in our research is 
that in early untreated PD the majority of patients have apathy without comorbid 
depression or severe cognitive problems. The significant association between apathy 
and more severe motor symptoms in these patients, highlights the need for further 
studies exploring the effect of dopaminergic medications, especially dopamine 
agonists with high affinity to D3 receptors that are largely expressed in the nucleus 
accumbens and ventral striatum, on the symptoms of apathy. However, large 
randomized placebo-controlled studies are needed for this purpose. Another 
important finding in the present thesis is that a more rapid decline in progression of 
speech problems and axial symptoms were associated with incident apathy in patients 
with moderate to advanced PD. Given the considerable clinical heterogeneity in PD, 
identification of certain motor subtypes of the disease may serve as prognostic 
indicators of patients at risk of developing apathy. Last, but not least, there is a need 
for valid and reliable assessment tools to evaluate apathy in PD and other 
neurodegenerative disorders. Existing apathy scales commonly used in PD patients 
should be validated against newly proposed consensus criteria to assess sensitivity 
and specificity among patients with or without apathy. The confounding influence of 
depressive symptomatology, cognitive decline and motor fluctuations (on versus off 
states) on the performance of apathy rating scales, as well as reliability of patient-
rated versus caregiver-rated instruments should also be evaluated. 
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9. Conclusions 
 
The aims of this thesis were to describe and achieve a better understanding of apathy 
as a neuropsychiatric disturbance in community-based patients with PD from the time 
of diagnosis to more advancing stages.  
 
We have shown that the UPDRS part I is an adequate screening instrument for apathy 
in patients with PD, using proposed diagnostic criteria for apathy as a guide. 
However, in clinical practice more sophisticated apathy rating scales are 
recommended for diagnostic accuracy.  
 
The occurrence and clinical correlates of apathy in early versus more advanced stages 
of PD were examined in two different community-based cohorts. We found that the 
frequency of apathy increased from 23% in early untreated PD, to 38% in patients 
with a mean disease duration of nine years, and that after 17 years of PD 63% had 
developed apathy. Unfortunately, due to different assessment tools the severity of 
apathy symptoms was not examined. However, the frequency of comorbid depression 
and especially severe cognitive dysfunction and dementia increased during 
progression of PD. Also, apathy was significantly associated with motor severity in 
both early untreated PD and in those with a mean disease duration of nine years, 
implying a common underlying pathophysiological mechanism. Somewhat 
unexpectedly, we observed a significant association between apathy and male gender 
in patients with early PD. Possible explanations for this finding are low testosterone 
levels in elderly men and the use of caregiver-rated assessment tools. In the same 
cohort, apathy contributed to considerable distress in more than 50% of the caregivers 
of those with apathy. 
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In a prospective longitudinal cohort study of more advanced cases of PD, we showed 
that apathy was a persistent behavioural problem with high incidence and prevalence 
over time. We found that dementia and a more rapid decline in speech and axial 
impairment, features predominantly associated with dysfunction in non-dopaminergic 
pathways, were independent risk factors for incident apathy. 
 
In summary, apathy is a common neuropsychiatric disturbance at all stages of PD, 
contributes to considerable caregiver distress in early disease, and is mostly 
associated with motor severity, depression and cognitive dysfunction. Rapid 
progression of speech problems and axial impairment may be a useful preclinical 
marker for incident apathy in PD. Although our findings indicate that dopaminergic 
dysfunction may explain the occurrence of apathy in the early stages of PD, whereas 
non-dopaminergic deficits are mostly responsible for apathy in more advanced stages, 
future studies should explore this hypothesis by using validated apathy rating 
instruments, functional brain imaging and biologically relevant biomarkers. 
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